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Abstract 
The European Union Reference Laboratory for Feed Additives (EURL-FA), hosted by the 
Joint Research Centre (JRC), a Directorate General of the European Commission, has 
been mandated by the Directorate General for Health and Food Safety (DG SANTE) to 
organise a proficiency test (PT) among appointed National Reference Laboratories (NRLs) 
in the frame of its control activities (according to the Regulation (EC) No 882/2004 [1]). 
The aim of this PT was to assess the capacity of the NRLs to correctly determine selected 
authorised coccidiostats added to feed matrices at realistic authorised levels and at 
cross-contamination levels. Thirty-six European National and Official Control laboratories 
were invited and twenty-nine laboratories registered to the 2017 PT exercise. Twenty-
five of the registered laboratories reported results for the analyses.  
The test items used in this exercise were produced by the JRC. Purchased commercial 
poultry compound feed, tested by the EURL-FA Control as being blank for the target 
analytes, was milled and ground and then spiked with the required coccidiostat standard 
solution or with the relevant authorised feed additive. The first item was spiked with a 
standard solution containing monensin, narasin and diclazuril, at cross-contamination 
level (MAT 1). The second test item (MAT 2) was spiked with an authorised feed additive 
Maxiban®, containing narasin (narasin AL) and nicarbazin, at additive level. MAT 1 and 
MAT 2 were subsequently homogenised and distributed in glass bottles. All bottles were 
labelled ensuring a random number encoding and dispatched to all registered participants 
on 27 June 2017. 
Laboratories were informed of the composition of the test material regarding the 
composition in coccidiostats for MAT 2 and had therefore only to quantify the content. For 
MAT 1 the laboratories had to screen for the presence of all 11 authorised coccidiostats 
and to quantify the detected ones.  
The assigned values (xpt) for the mass content of monensin, diclazuril and narasin in 
MAT 1 were calculated from the formulation as recommended by the IUPAC harmonized 
protocol [2]. The uncertainties for the assigned values (u(xpt)) were calculated according 
to the ISO Guide for the Expression of Uncertainty in Measurement (GUM) [3].  
For narasin and nicarbazin in MAT 2, no assigned value was set since the criterion for 
sufficient homogeneity could not be met.  
Participants were invited to report their measurement uncertainties. This was done by 
twenty-three out of twenty-five reporting participants for monensin and narasin, 
seventeen for diclazuril, and twenty for narasin AL and nicarbazin. 
Laboratory results were rated using z and ζ (zeta) scores in accordance with ISO 
13528:2015 [4]. The relative standard deviation for proficiency assessment (σpt) for each 
assigned value was calculated using the relevant Horwitz [5] or modified Horwitz 
equation [6]. The z scores obtained were considered satisfactory if their absolute values 
were equal to or below 2. 
The outcome of this PT exercise is mixed; the percentage of satisfactory results reported 
by the laboratories for MAT 1 is 88%, 80% and 57% for monensin, narasin and diclazuril 
respectively. For narasin AL and nicarbazin in MAT 2, no scoring was computed but the 
data reported by the laboratories were examined. In general, there was good agreement 
among the values of mass content of narasin and nicarbazin reported results.  
The laboratories also reported qualitative results as regards the presence of one or more 
of the other authorised coccidiostats. On the whole, the rate of false positive results was 
of 4% for robenidine, lasalocid, salinomycin and maduramicin; 5% for nicarbazin; 8% for 
decoquinate; and 0% for all the others. Two laboratories did not quantify diclazuril in 
MAT 1 while stating a limit of quantification of the method used lower than the assigned 
value, leading to a false negative rate of 9% for this analyte. One laboratory could not 
quantify diclazuril in MAT 1 due to the lack of sensitivity of the method used. 
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1 Introduction 
Feed additives are authorised within the European Union according to Regulation (EC) 
No 1831/2003 of the European Parliament and of the Council [7]. The Commission 
Regulations authorising the specific feed additives often contain conditions of use (such 
as the maximum content) requiring the availability of suitable methods of analysis for 
official control in feedingstuffs. All feed additives authorised within the European Union 
are listed in the Register of Feed Additives [8] maintained by the European Commission. 
Coccidiostats are the only anti-bacterial substances still authorised as feed additives. 
They are classified in the category 5 (Coccidiostats and histomonostats) and constitute 
the main choice to fight against coccidiosis. In this study, the two coccidiostats targeted 
at additive level are contained in the feed additive Maxiban® authorised via the 
Commission Regulation (EU) No 885/2010 amending Regulation (EC) No 2430/1999 [9]. 
It is well known that during the production of feed containing coccidiostats as feed 
additives, unavoidable carry-over of the coccidiostats from feed which is covered by the 
authorisation (target feed) to feed which must not contain coccidistats (non-target feed) 
occurs when the same production lines are used. A too high concentration of 
coccidiostats in non-target feed would harm non-target animal species. Additionally, as 
all anti-bacterial substances, coccidiostats may be a risk for human health because the 
presence of their residues in foodstuffs could cause toxic effects, directly in sensitive 
individuals and also indirectly because their widespread usage could be responsible for 
the promotion of resistant strains of bacteria. The EU legislation addressed both concerns 
and established maximum limits for the unavoidable carry-over of coccidiostats or 
histomonostats (Commission Regulation (EU) No 574/2011 [10] amending Annex I to 
Directive 2002/32/EC) and National Reference Laboratories and Official Control 
laboratories are in charge of implementing the surveillance monitoring control plan in the 
Member States as regards these substances in feed. Enforcing the legislation and 
performing the compulsory monitoring requires the availability of reliable analytical 
methods. In a continuous effort to be updated on the reliability of analytical results 
delivered by laboratories in charge of ensuring the official control of coccidiostats in feed, 
the European Commission’s Directorate General for Health and Food Safety (DG SANTE) 
requested the EURL-FA Control to organise an inter-comparison study for the 
determination of coccidiostats at cross-contamination levels in compound feed in 2012, 
2013 and 2014. Results obtained were in general satisfactory and DG SANTE requested 
the EURL-FA Control to perform a fourth exercise in 2017. As in 2014, proficiency of the 
laboratories to address authorised levels was also assessed. The aim of this series of 
exercises is to progressively assess all authorised coccidiostats. 
This report summarises the outcome of the exercise.  
 
2 Scope 
As stated in Regulation (EC) No 882/2004 [1] one of the core duties of EURLs is to 
organise interlaboratory comparisons for the benefit of NRLs.  
The scope of this PT was to assess the proficiency of the participating laboratories to 
correctly determine coccidiostats in potentially contaminated feed samples and also at 
authorised level in compound feed samples, and to report results in the specified units 
within a defined time frame. The laboratories were requested to analyse feed samples 
applying the analytical methods referred to in the respective authorisation legislation or 
their own analytical method and reporting the results to the organiser of the study.  
Participating laboratories were informed of the sample composition regarding 
coccidiostats in the material prepared at authorised level, thereby reflecting the situation 
of typical control conditions; for the materials containing the coccidiostats at cross-
contamination levels, such information was not provided and the participants had to 
screen for the presence of coccidiostats and to quantify and report the ones detected.  
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The reported results were assessed following the administrative and logistic procedures 
of the JRC Unit in charge of the EURL-FA Control, which is accredited for the organisation 
of PTs according to ISO 17043:2010 [11].  
This PT is identified as EURL-FA 2017-1. 
 
3 Design of the exercise 
3.1 Time frame 
The proficiency test was agreed upon by the EURL-FA Control and DG SANTE and was 
announced to the NRL network at the 5th EURL-FA Control Workshop held in Brussels on 
November 22-23, 2016. A call for participation to the PT exercise was launched on May 
03, 2017 (Annex 1). The samples were dispatched to the participants on June 27, 2017. 
The dispatch was monitored by the PT coordinator using the messenger's parcel tracking 
system on the Internet. The initial reporting deadline set to July 27, 2017 was further 
extended to August 27, 2017. 
3.2 Confidentiality 
The procedures used for the organisation of PTs are accredited according to ISO/IEC 
17043:2010 [11] and guarantee that the identity of the participants and the information 
provided by them is treated as confidential. However, the lab codes of the NRLs that 
have been appointed in line with Regulation (EC) No 882/2004 may be disclosed to 
DG SANTE upon request for the purpose of an assessment of their (long-term) 
performance. 
3.3 Distribution 
Each participant received:  
- One bottle of test item 1 containing approximately 20 g of material; 
- One bottle of test item 2 containing approximately 50 g of material; 
- An accompanying letter with instructions for sample handling and reporting 
(Annex 2); and  
- A "Confirmation of receipt" form to be sent back to the EURL-FA Control after 
receipt of the test items and the individual lab code (Annex 3). 
The instructions on how to report the results on-line and to fill in the questionnaire were 
sent in an electronic message on July 17, 2017 to each participant. 
3.4 Instructions to participants 
Detailed instructions were given to all participants in the 'Accompanying letter' and in the 
electronic message for reporting mentioned above.  
Laboratories were asked to perform the analysis on test items as received, applying the 
method they normally apply within their official control strategy. The participants were 
asked to report the content of the respective coccidiostat in mg kg-1 of compound feed 
(given with 3 decimals), with the associated expanded measurement uncertainty for a 
coverage factor of 2. In addition, details on the analytical method (e.g. sample 
preparation, instrumental technique) used to perform the measurements had also to be 
reported together with explanations on how the reported measurement uncertainty was 
estimated. 
All results and questionnaire answers had to be reported on-line using the in-house 
developed MILC® interface. Each laboratory was assigned a unique code and a unique 
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participant key to be used for the results' reporting. Both codes were individually 
communicated in acknowledgement of reception form (Annex 3). 
4 Test items 
4.1 Preparation 
A commercial compound feed for laying hens - declared not to contain any coccidiostat 
(blank feed) - was purchased at the local market in Geel (Belgium) and used to produce 
the PT test items. The producer reported the following composition on the label: 
Small pellets – compound feed for laying hens 
Analytical Constituents: 11.70% crude ash, 5.25% cellulose, 15.50% proteins, 
4.00% fat, calcium carbonate, sodium chloride, monocalcium phosphate. 
Nutritional additives: vitamins. 
Other main ingredients: corn, soya, sunflower by-product, wheat, gluten, 
     beet. 
According to the label samples contained various feed additives, but no coccidiostats.  
The compound feed was ground in a Stephan UM12 cutter / mixer and sieved to obtain a 
top particle size of 1 mm although X90 was already below 700 µm. The ground and sieved 
compound feed was then tested at the EURL-FA Control laboratories using High 
Performance Liquid Chromatography Tandem Mass Spectrometry (HPLC-MS/MS) to 
ensure that no measurable contamination by any authorised coccidiostat was present. 
The sample set was comprised of two different test items, MAT 1 and MAT 2 containing 
different target analytes at different mass fraction levels.  
4.1.1 Test item 1  
Test item 1 (MAT 1) contained monensin, narasin, and diclazuril at cross-contamination 
level for e.g. chickens for fattening, chickens reared for laying (< 16 weeks) (monensin), 
turkeys, rabbits, equine species, laying birds and chickens reared for laying (> 16 weeks) 
(narasin) and laying birds, chickens reared for laying (> 16 weeks) and turkeys for 
fattening (> 12 weeks) (diclazuril) as established by Regulation (EU) No 574/2011 and 
summarised in the following table: 
Analyte Mass fraction (mg kg-1) 
relative to a feed with a 
moisture content of 12% 
Monensin sodium 1.25 
Narasin 0.7 
Diclazuril  
 
Sufficient blank compound feed material to cover the total required amount for the PT 
was taken for MAT 1 and spiked with an appropriate standard solution containing 
monensin, narasin, and diclazuril. The nominal mass fractions of the selected 
coccidiostats were set close to the cross-contamination levels as defined in the legislation 
[10]. Homogeneous impregnation was ensured by thorough agitation of the compound 
feed. The solvents in excess were subsequently evaporated until the compound feed 
obtained had a powder aspect with no aggregates. The bulk material of MAT 1 was 
subsequently homogenised using a Dynamix CM200 mixer (WAB, Muttenz, CH) 
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employing a Turbula mixing action and divided into 20-g sub-samples using a vibrating 
feeder and a balance. 
4.1.2 Test item 2  
Test item 2 (MAT 2) contained narasin and nicarbazin at additive level. The processing of 
this complex mixture was challenging; step-wise mixing of the ground and sieved blank 
feed with the appropriate quantity of the feed additive Maxiban® was performed. 
According to Regulation (EC) No 885/2010 [9] Maxiban® is a complex preparation 
consisting of corn cob grit or rice hull and vermiculite as main components and 
containing narasin and nicarbazin at equivalent target mass fractions of 80 g kg-1. 
According to the certificate of analysis provided by the additive authorisation holder, 
Maxiban® contained nicarbazin at 78 mg g-1 and narasin at 81 mg g-1, respectively. 
Furthermore, this Regulation establishes a minimum and maximum content of these 
coccidiostats in compound feed of 40 mg kg-1 and 50 mg kg-1, respectively. The material 
was diluted with the blank compound feed to obtain a target mass fraction of about 40 
mg kg-1 for each coccidiostat, corresponding to a total dilution factor of 2000. 
Initially the particle size distributions of the two powders were measured with the aim of 
matching as best as possible the respective blank poultry feed and Maxiban® fractions to 
be mixed. It should however be noted that the blank poultry feed had a larger proportion 
of fine particles. Step-wise dilution of the feed additive Maxiban® with the blank poultry 
feed was performed applying twice a 1:4 (Maxiban®:blank poultry feed) ratio then 
successive 1:10 ratios (resulting mixture:blank poultry feed) per dilution step until mass 
fractions close to the additive level for narasin and nicarbazin as defined in the legislation 
[9] were achieved. The bulk material of MAT 2 was further homogenised using the 
Dynamix CM200 mixer and divided into 50 g sub-samples using a vibrating feeder and a 
balance. 
All sub-samples were filled into glass bottles, then closed with a screw-cap with a break 
ring, labelled and stored at -20 °C until further dispatch and/or analysis. 
4.2 Homogeneity and stability 
Measurements for the homogeneity and stability studies were performed by the EURL-FA 
Control. HPLC-MS/MS was used after liquid-solid extraction (5 g of sample in a 
acetonitrile/methanol/water mixture) to determine the mass fraction of the target 
analytes.  
The statistical treatment of data was performed by the EURL-FA Control. The analytical 
results and the statistical evaluation of the homogeneity and stability studies are 
presented in Annex 4, Annex 5, and Table 1. 
4.2.1 Homogeneity 
Homogeneity was evaluated according to ISO 13528:2015 [4]. Ten bottles of each test 
item were randomly selected. Two aliquots from each bottle were analysed in duplicate. 
The individual results of the sub-sample duplicates were subjected to analysis of 
variances (ANOVA). The contribution from homogeneity (uhom) to the standard 
uncertainty of the assigned value (u(xpt)) was calculated using SoftCRM [12]. 
4.2.1.1 Test item 1 
The within-bottle variation was sufficiently lower than the target standard deviation and 
the F-test confirmed the homogeneity of MAT 1 for monensin, narasin and diclazuril, 
respectively (Annex 4).  
4.2.1.2 Test item 2 
For MAT 2, the results showed a too large variability for narasin AL and nicarbazin (Annex 
4), which may be attributed to particle segregation in the material (the heaviest fraction 
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may have settled at the bottom of the bottle). It appears as if the active substances were 
associated with heavier particles. Since the participating laboratories were not instructed 
to thoroughly shake the sample before starting the analysis, it was decided not to score 
the laboratories for the analysis of MAT 2, thus avoiding unfair performance assessment 
due to the lack of homogeneity. 
4.2.2 Stability 
The stability study confirmed that the two materials were stable at the recommended 
storage temperature of -20 °C over the whole period of the PT (16 weeks, from dispatch 
of the samples to participants till the deadline for reporting of results) (Annex 5). Hence, 
the uncertainty contribution due to stability was set to zero (ust = 0).  
5 Assigned values and corresponding uncertainties 
Table 1 summarises the assigned value for the mass fractions of monensin, narasin and 
diclazuril, the associated uncertainty values and the standard deviation for proficiency 
assessment. 
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Table 1. Assigned value (xpt) and corresponding standard uncertainty (u(xpt), k=1); 
uncertainty contributions due to formulation (uform) and homogeneity (uhom); and 
standard deviation for proficiency assessment calculated as specified under 
chapter 5.3 (pt).  
All values are expressed in mg kg-1, relative to feed with a moisture content of 
12 %. 
 Analyte xpt uform uhom u(xpt) pt u(xpt)/pt 
MAT 1 Monensin 1.156 0.006 
(0.5 %) 
0.036 
(3.1 %) 
0.036 
(3.1 %) 
0.180 
(15.5 %) 
0.20 
Narasin 0.670 0.003 
(0.4 %) 
0.021 
(3.1 %) 
0.021 
(3.1 %) 
0.113 
(16.9 %) 
0.19 
Diclazuril 0.0100 0.0001 
(1.0 %) 
0.0004 
(4.0 %) 
0.0004 
(4.0 %) 
0.0022 
(22 %) 
0.18 
 
5.1 Assigned values 
5.1.1 Test item 1 
The assigned values (xpt) for monensin, narasin and diclazuril in MAT 1 were set as the 
nominal value calculated from the formulation as recommended by the IUPAC 
harmonized protocol [2], corrected for purity and further adjusted to 12% moisture. 
 
For monensin and narasin, the following calculation is perfomed:  
𝑥𝑝𝑡 = 0.88(
𝑚𝑟𝑒𝑓 𝑠𝑡𝑑
𝑚𝑏𝑙𝑎𝑛𝑘
×
𝑉2×𝑉4
𝑉1×𝑉3
× 𝑝 × 1000)/(1 −
%𝑚𝑜𝑖𝑠.
100
)  Eq. (1) 
where 
xpt is the assigned mass fraction of monensin or narasin, in mg kg
-1 of feed 
mref std is the weighed mass of the corresponding reference standard, in mg 
V1 is the volume of solvent added for the stock standard solution, in ml 
V2 is the volume of stock standard solution of the measurand used to produce  
    the spiking solution, in ml 
V3 is the volume of solvent added to V2 to produce the spiking solution, in ml 
V4 is the volume of the spiking solution used for spiking the blank feed with  
    the corresponding measurand, in ml 
mblank is the mass of blank feed to be spiked, in g 
% mois. is the percentage of water content measured in the blank feed 
p is the purity of the measurand standard substance as declared on the certificate 
   of analysis provided by the supplier. 
For diclazuril an intermediate standard solution was used before producing the spiking 
solution due to the low value targeted as final concentration in the feed. The nominal 
value is therefore calculated as follows:  
𝑥′𝑝𝑡 = 𝑥𝑝𝑡 ×
𝑉𝑎
𝑉𝑏
    Eq. (2) 
where 
x'pt is the assigned mass fraction of diclazuril in mg kg
-1 of feed 
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Va  is the volume of stock standard solution of diclazuril, in ml 
Vb  is the volume of solvent added to Va to produce the intermediate  
     standard solution of diclazuril in ml. 
5.1.2 Test item 2 
No assigned values (xpt) for narasin AL and nicarbazin in MAT 2 were set because of the 
insufficiently homogeneous material. However, indicative values for Narasin AL and 
Nicarbazin of 39 and 37 mg kg-1 (relative to feed with a moisture content of 12 %) were 
calculated from the formulation, corrected for the purity specified in the certificate of 
analysis of the feed additive, taking into account the measured water content of the 
blank feed and applying the dilution factors used in the step-wise. 
 
5.2 Associated uncertainties 
The associated standard uncertainties of the assigned values (u(xpt)) were calculated 
following the law of uncertainty propagation, combining the standard measurement 
uncertainty of the sample preparation according to the formulation (uform) with the 
standard uncertainty contributions from homogeneity (uhom) and stability (ust), in 
compliance with ISO 13528:2015 [4]: 
𝑢(𝑥𝑝𝑡) = √𝑢𝑓𝑜𝑟𝑚
2 + 𝑢ℎ𝑜𝑚
2 + 𝑢𝑠𝑡
2     Eq. (3) 
The standard uncertainty uform is estimated according to the ISO Guide for the Expression 
of Uncertainty in Measurement (GUM) [3]:  
𝑅𝑆𝑢(𝑥𝑝𝑡) = √∑ 𝑅𝑆𝑢𝑖
2    Eq. (4) 
where RSu(xpt) and RSui are the relative standard uncertainties associated (i) to the 
assigned value of the mass fraction, and (ii) to each component of Equation (1) or 
Equation (2), respectively.  
Note 1:  The type B uncertainty on the volume and mass used in Equation (1) and (2) 
are assumed to follow a triangular and a rectangular distribution respectively. 
Similarly for purity, providers often provide a 'minimum purity', with an 
expected maximum purity of 100 %; hence the corresponding distribution is 
assumed to be rectangular. Following the Eurachem guide [13], the calculations 
of the standard uncertainty ui and the relative standard uncertainty RSDui are 
calculated as follows: 
 For a triangular distribution:   𝑢𝑖=
𝑎
√6
   Eq. (5) 
 For a rectangular distribution: 𝑢𝑖=
𝑎
√3
   Eq. (6) 
where ui is the standard uncertainty (associated to volume, mass or purity) and ± a 
is the limit given without a confidence level (maximum possible error of the input 
estimate) 
 
5.3 Standard deviation for proficiency assessment, pt 
The target relative standard deviations for proficiency assessment (σpt) presented in 
Table 1 were calculated using the original Horwitz equation [5] when the mass ratios 
were between 1.2 x 10-7 and 0.138 (monensin and narasin). When the mass ratio was 
below 1.2 x 10-7 (diclazuril), σpt was set to 22 % according to the Horwitz Equation 
modified by Thompson [6]. 
 11 
6 Evaluation of results and discussion 
6.1 Scores and evaluation criteria 
The individual laboratory performance was expressed in terms of z and ζ scores in 
accordance with ISO 13528:2015 [4] : 
𝑧 =
𝑥𝑖−𝑥𝑝𝑡
𝜎𝑝𝑡
  Eq. (8) 
𝜁 =  
𝑥𝑖− 𝑥𝑝𝑡
√𝑢2(𝑥𝑖)+𝑢2(𝑥𝑝𝑡)
 Eq. (9) 
 
where 
xi is the measurement result reported by a participant, 
xpt is the assigned value, 
u(xi) is the standard measurement uncertainty reported by a participant, 
u(xpt) is the standard measurement uncertainty of the assigned value, 
σpt is the standard deviation for proficiency test assessment. 
 
The assigned values (xpt) and the respective uncertainties are presented in  
Table 1.  
 
The interpretation of the z and ζ scores is done as follows: 
 |score| ≤ 2  satisfactory performance  (green in Table 4 and Annex 6)  
    2 < |score| < 3  questionable performance (yellow in Table 4 and Annex 6)  
 |score| ≥ 3  unsatisfactory performance (red in Table 4 and Annex 6)  
 
The z score compares the participant's deviation from the assigned value with the target 
standard deviation for proficiency test assessment (σpt) used as common quality 
criterion.  
All participants were requested to report their estimation of the associated expanded 
uncertainties (coverage factor of 2) together with the measured values for the content in 
coccidiostats, in mg kg-1. Calculation of the ζ score was therefore also part of the 
evaluation.  
The ζ score states if the laboratory result agrees with the assigned value within the 
respective uncertainty. The denominator is the combined uncertainty of the assigned 
value u(xpt) and the measurement uncertainty as stated by the laboratory u(xi). The 
ζ score includes all parts of a measurement result, namely the expected value (assigned 
value), its measurement uncertainty in the unit of the result as well as the uncertainty of 
the reported values. An unsatisfactory ζ score can either be caused by an inappropriate 
estimation of the concentration, or of its measurement uncertainty, or both. 
The standard measurement uncertainty of the laboratory u(xi) was calculated by dividing 
the reported expanded uncertainty by the coverage factor, k equal to 2 unless otherwise 
specified by the participant. When no uncertainty was reported, the ζ score of the 
laboratory was estimated setting the uncertainty u(xi) to zero. When k was not specified, 
the reported expanded measurement uncertainty was considered as the half-width of a 
rectangular distribution; u(xi) was then calculated by dividing this half-width by √3, as 
recommended by Eurachem [13]. 
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Uncertainty estimation is not trivial; therefore an additional assessment was provided to 
each laboratory reporting measurement uncertainty, indicating how reasonable their 
measurement uncertainty estimation was.  
The standard measurement uncertainty from the laboratory u(xi) is most likely to fall in a 
range between a minimum and a maximum allowed uncertainty (case a": 
umin ≤ ui ≤ umax). umin is set to the standard uncertainties of the assigned values u(xpt). It 
is unlikely that a laboratory carrying out the analysis on a routine basis would determine 
the measurand with a smaller measurement uncertainty than the expert laboratories 
chosen to establish the assigned value. umax is set to the standard deviation accepted for 
the PT assessment (pt). Consequently, case "a" becomes: u(xpt) ≤ u(xi) ≤ pt.  
If u(xi) is smaller than u(xpt) (case "b") the laboratory may have underestimated its 
measurement uncertainty. Such a statement has to be taken with care as each 
laboratory reported only measurement uncertainty, whereas the measurement 
uncertainty associated with the assigned value also includes contributions for 
homogeneity and stability of the test item. If those are large, measurement uncertainties 
smaller than u(xpt) are possible and plausible.  
If u(xi) is larger than pt (case "c") the laboratory may have overestimated its 
measurement uncertainty. An evaluation of this statement can be made when looking at 
the difference between the reported value and the assigned value: if the difference is 
smaller than the expanded uncertainty U(xpt) then overestimation is likely. If the 
difference is larger but xi agrees with xpt within their respective expanded measurement 
uncertainties, then the measurement uncertainty is properly assessed resulting in a 
satisfactory performance expressed as a ζ score, though the corresponding performance, 
expressed as a z score, may be questionable or unsatisfactory.  
It should be pointed out that "umax" is a normative criterion when set by legislation. 
 
6.2 General observations 
Although the network for the EURL-FA Control is still not complete, the number of 
Member States that officially nominated an NRL for Feed Additives Control increased from 
11 (in 2016) to 14 countries. As in previous years, the EURL-FA Control invited in 
addition to these NRLs, for which participation in the PT (or nomination of a representing 
laboratory) is compulsory, all NRLs for Feed Additives Authorisation as well as Official 
Control laboratories from EU and associated countries (Switzerland). Out of 36 
laboratories invited to participate in the exercise, 29 laboratories from 21 countries 
registered, and 25 reported results. 
Few laboratories did not report any uncertainty assessment. Most laboratories responded 
comprehensively to the questionnaire included in the reporting form. All results were 
included in the final evaluation. 
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Figure 1 gives an overview of the geographical distribution of participating laboratories. 
Figure 1. Country of origin of the participants – NRLs and non NRLs laboratories 
 
 
 
 
 
 
 
 
 
 
 
 
6.3 Laboratory results and scoring 
6.3.1 Performances 
The results reported by the participants for the total content of monensin, narasin, 
diclazuril, narasin AL and nicarbazin are given in Annex 6, which includes the table of 
results, the graphical representation and the corresponding Kernel density plot - obtained 
using the software available from the Statistical Subcommittee of the Analytical Methods 
Committee of the UK Royal Society of Chemistry [14]. 
For MAT 1 (with coccidiostats at cross-contamination level), twenty-two, twenty, and 
thirteen laboratories reported results with a |z|  2 for monensin, narasin and diclazuril, 
respectively. Three laboratories reported questionable results for monensin and diclazuril, 
four for narasin. No laboratory reported unsatisfactory results for monensin, one had 
unsatisfactory results for narasin and seven for diclazuril (Annex 6). The technical 
reasons for those biased results should be further investigated by these laboratories.  
Figure 2 shows the laboratory performances assessed by the z' and ζ scores for 
all reporting laboratories. 88 %, 80 % and 57 % of the participants having 
reported results for monensin, narasin and diclazuril, respectively performed 
satisfactorily according to the z score. According to the ζ score, this percentage of 
satisfactory percentage was 80 %, 84 % and 57 %, respectively. 
Similarly, Figure 3 displays the laboratory performances assessed by the z' and ζ scores 
extracted for the control NRLs (only). 82 %, 64 % and 73 % of the NRLs for control 
having reported results for monensin, narasin and diclazuril, respectively 
performed satisfactorily according to the z score. According to the ζ score, this 
percentage of satisfactory percentage was 82 %, 73 % and 45 %, respectively. 
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Figure 2. Distribution of the z and ζ scores values for all laboratories 
 
 
 
The number of reporting laboratories for each category is given in the graphs 
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Figure 3. Distribution of the z and ζ scores values for control NRLs (only) 
 
 
 
The number of reporting laboratories for each category is given in the graphs 
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Table 2.  Statistical comparison of the robust mean with the assigned value for each 
analyte. 
 Analyte 
xpt 
mg kg-1 
σpt 
% 
Robust mean 
mg kg-1 
Robust std 
deviation  
mg kg-1 
Robust 
RSD(1) % 
MAT 1 
Monensin 1.156 15.5 1.233 0.209 16.9% 
Narasin 0.670  16.9 0.753 0.144 19.2% 
Diclazuril 0.010  22.0 0.009 0.004 38.5% 
MAT 2 
Narasin AL -(2) - 44.995 14.001 31.1% 
Nicarbazin -(2) - 40.017 12.542 31.3% 
(1) RSD: Relative Standard Deviation; (2) No assigned value set  
 
Lastly the robust means calculated according to ISO 13528:2015 [4] from the results 
reported are statistically comparable to the corresponding assigned values of the target 
coccidiostats investigated (Table 2).  
6.3.2 Discussion for the nicarbazin results 
Although no scoring was performed for narasin AL and nicarbazin in MAT 2, all the results 
reported by the laboratories were examined. It is worth to remind that when analysing 
the content of authorised coccidiostats at additive level, a potential non-compliant result 
shall be confirmed by utilizing the official method as defined in the authorizing legislation 
[9].  
Overall the results are in good agreement among the laboratories. Some laboratories 
report results for nicarbazin that differ significantly from the robust mean and/or the 
indicative value of the mass fraction. One reason may be that the reported result was not 
expressed in nicarbazin-equivalent but in 4,4'-dinitrocarbanilide (DNC), while the 
regulated value is for nicarbazin. The data treatment was based on the assumption that 
results were expressed as nicarbazin, as requested by legislation.  
Nicarbazin is a complex of two compounds, namely 4,4'-dinitrocarbanilide (DNC) and 4,6-
dimethyl-2-pyrimidinol (HDP). The active substance is DNC; DNC is also the substance 
being quantified in LC-MS/MS. The calibrations curves are therefore performed for DNC. 
Nicarbazin has a molar mass MNic of 426.38 g mol
-1 while the molar mass of DNC MDNC is 
302.25 g mol-1 (and the molar mass for HDP is 124.14 g mol-1). A mass fraction of 
39  mg  kg-1 of nicarbazin would correspond to a mass fraction of 27.646 mg kg-1.  
Additionally, the purity of the nicarbazin standard used to prepare the calibration curve 
should also be taken into account, as well as the purity of the DNC in the nicarbazin. 
Both values derive from the certificate of analysis provided with the standard and from 
the area % of the DNC peak. As an example, if the certificate of analysis of the standard 
provides a value for the purity of nicarbazin of 98.7 % and the area % of the DNC peak is 
92.23 %, then the purity of DNC is 0.9223 x 0.987=0.9103. The result of measurement 
obtained from the calibration curve should then be corrected by the purity (multiplying 
the obtained result of measurement) to get the correct value in DNC. To express the 
result as Nicarbazin, the latter has to be multiplied by the MNic / MDNC ratio. 
6.3.3 False positives and false negatives 
Another important aspect for official control is the percentage of false positive (FP) and 
false negative (FN) rates of the method used. For a screening method, it is of key 
importance that the FN rate is as low as possible, whereas for a confirmatory method, 
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the FP rate should be kept to a minimum. Ideally, both rates should be as low as possible 
but the necessary compromises are to be done depending on the scope of the method. 
In this PT exercise, if a sample was analysed for a selected analyte and the determined 
mass fraction would be lower than the limit of detection, then the analyte should be 
reported as "not detected" and the reported result should be "lower than LOD"; likewise, 
if a sample was analysed for a selected analyte and the determined mass fraction would 
be lower than the limit of quantification, then the analyte should be reported as 
"detected" and the reported result should be "lower than LOQ". If an analyte present in 
the sample is reported as "not detected" or "detected" but with a mass fraction "lower 
than LOQ" and the laboratory reported an LOQ which was lower than the assigned value 
of the measurand then the result was classified as a "true" FN. Alternatively, if the 
method used was e.g. not sensitive enough for the scope of the analysis, the non-
detection of the analyte is obviously due to a lack of sensitivity.  
In the questionnaire to the participants, information on the limits of detection (LOD) and 
quantification (LOQ) was requested. Based on this information (Annex 7), the FN results 
were therefore also discriminated during the evaluation. 
A result is considered as "FP" if the laboratory detects and reports a numerical value 
(above the LOQ) for an analyte which was not present in the given sample. 
Table 3 displays the percentages of false negatives and false positives in this study. 
Table 3. False positive and false negative rates for each target coccidiostat. 
  False positive 
rate, % 
False negative rate, % 
 N True Lack of sensitivity 
Monensin 25 - - - 
Narasin 25 - - - 
Diclazuril 23 - 9% 4% 
Nicarbazin 22 5% (MAT 1) - - 
Narasin AL 22 - - - 
Robenidine 25 4% (MAT 1)   
Decoquinate 25 8% (MAT 1)   
Lasalocid 25 4% (MAT 1)   
Salinomycin 25 4% (MAT 1)   
Maduramicin 25 4% (MAT 1)   
N: number of reporting laboratories 
6.4 Additional information extracted from the questionnaire 
Additional information was gathered from the questionnaire filled in by the participants. 
A compilation of the method parameters used by the participants is given in Annex 8.  
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7 Follow-up of laboratories over four exercises 
This proficiency test exercise, dedicated to the National Reference Laboratories and 
Official Control Laboratories, is the fourth exercise organised by the EURL-FA Control 
targeting coccidiostats. A summary of the performance of laboratories having 
participated in the four PTs for the determination of monensin, narasin and diclazuril is 
presented in Table 4 to assess the evolution of the laboratory performance (as 
satisfactory, questionable and unsatisfactory z scores). This table should be used by each 
laboratory to monitor their performance and to identify any potential trend. 
 
Table 4.  Laboratory performance evolution across the four PTs targeting coccidiostats, 
per analyte.  
 
 
 
LabCode_2017
2012 2013 2014 2017 2012 2013 2014 2017 2012 2013 2014 2017
L01
L02
L03
L04
L05
L06
L07
L08
L10
L11
L12
L13
L14
L15
L16
L17
L18
L19
L20
L21
L22
L23
L24
L25
L26
L27
L28
L29
NRL-FAC
NRL-FAA
OCL
Monensin Narasin Diclazuril
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8 Conclusions  
The 4th PT targeted coccidiostats at cross-contamination and additive levels in compound 
feed materials. Two test items, produced at JRC and containing two and three target 
coccidiostats respectively, were sent to each of the laboratories for analysis.  
In the test item spiked with coccidiostats at cross-contamination level participants were 
requested to screen for the presence or absence of authorised coccidostats and, if 
detected, to report the respective content(s) in mg kg-1 of feed with the associated 
measurement uncertainty. For the other test item where the target level was the one 
authorized in legislation, participants were informed of the composition in coccidiostats of 
the material and had to determine the content of each coccidiostat. However, 
participants were not instructed to thoroughly shake the sample before analysis; the 
measurements performed at JRC showed that this step had a significant impact of the 
homogeneity of the material. Consequently, laboratories were not assessed for their 
performance on the determination of the analytes contained in MAT 2.  
The individual laboratory performance was expressed in term of z and ζ scores.  
Proficiency test exercises shall be performed by the laboratories using the method they 
utilize within their control strategy. However, it should always be kept in mind that in 
case of litigation or non-compliance statement on a sample, the National Reference 
Laboratory or Official Control Laboratory shall confirm its result applying the official 
method of analysis.  
The statistical analysis showed that the proficiency of laboratories was variable 
depending on the analyte and of its mass fraction in the test material. More than 80 % of 
the results reported for monensin and narasin were satisfactory (only 57 % for diclazuril) 
12% to 16% of the laboratories reported questionable results; the rest of them got 
|z scores| higher than 3, requiring corrective actions to be implemented. The most critical 
analyte for control NRLs seems to be diclazuril, for which 18 % of the laboratories 
reported unsatisfactory results. 
Laboratories also reported qualitative results related to the presence of one or more of 
other authorised coccidiostats. Overall, the rate of false positive results was of 4 % for 
robenidine, lasalocid, salinomycin and maduramicin; 5 % for nicarbazin; and 8% for 
decoquinate. As for the false negatives, three laboratories did not quantify diclazuril in 
one test item, leading to a 'true' false negative rate of 9 % for this analyte; one of the 
false negative results was due to a lack of sensitivity of the method of analysis. 
Regarding the reported measurement uncertainties, the situation is in general consistent; 
the percentage of satisfactory ζ score is equal or close to the percentage of satisfactory 
z score, indicating that a realistic evaluation of uncertainties. However some laboratories 
largely overestimate their measurement uncertainty. Some laboratories did not report 
any measurement uncertainties. The measurement uncertainty is of paramount 
importance in cases of litigation and control laboratories must be able to report a sound 
measurement uncertainty. 
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Annex 1. Invitation letter sent to NRLs and other participants 
 
Ref. Ares(2017)2274774 
 
 
 
 
 
 
Dr Ursula Vincent 
Project Leader European Reference Laboratory for Feed Additives (control)  
(EURL-FA control) 
Joint Research Centre 
 
 
03 Mai 2017 
 
Call for participation in an inter-comparison study for the determination of 
authorised coccidiostats in feed at authorised and cross-contamination levels 
 
1. Introduction 
Feed additives are authorised within the European Union according to Regulation (EC) No 
1831/2003 requiring various criteria to be fulfilled including the need of providing 
suitable methods of analysis for official control in feedingstuffs. Coccidiostats are the only 
anti-bacterial substances still authorised as feed additives. They are classified in the 
category 5 (Coccidiostats and histomonostats) and constitute the main choice to fight 
against coccidiosis. 
It is well known that during the production of feed containing coccidiostats as feed 
additives, unavoidable carry-over of the coccidiostats from feed which is covered by the 
authorisation (target feed) to feed which must not contain coccidistats (non-target feed) 
occurs when the same production lines are used. A too high concentration of 
coccidiostats in non-target feed would harm non-target animal species. Additionally, as 
all anti-bacterial substances, coccidiostats may be a risk for human health because the 
presence of their residues in foodstuffs could cause toxic effects, directly in sensitive 
individuals and also indirectly because their widespread usage could be responsible for 
the promotion of resistant strains of bacteria. The EU legislation addressed both concerns 
and established maximum limits for the unavoidable carry-over of coccidiostats or 
histomonostats (Commission Regulation (EU) No 574/2011 amending Annex I to 
Directive 2002/32/EC). Enforcing the legislation and performing the compulsory 
monitoring requires the availability of reliable analytical methods. In a continuous effort 
to be updated on the reliability of analytical results delivered by laboratories in charge of 
ensuring the official control of coccidiostats in feed, the European Commission’s 
Directorate-General Health and Food Safety (formerly Health and Consumers) decided to 
organise an inter-comparison study for the determination of coccidiostats at cross-
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contamination levels in feed in 2012, 2013 and 2014. Results obtained were in general 
satisfactory and the Directorate-General Health and Food Safety requested the EURL-FA 
Control to perform a fourth exercise in 2017. This time, as in 2014, proficiency of the 
laboratories to address authorised levels will also be assessed. The aim of this series of 
exercises is to progressively asses all coccidiostats. This letter therefore constitutes the 
formal call for participation to this fourth proficiency testing exercise targeting 
coccidiostats at cross-contamination and authorised levels. 
As National Reference Laboratory representative, you are kindly reminded that according 
to Regulation (EC) No 882/2004 it is your duty to participate in PTs organised by the 
EURL-FA Control if you hold a mandate for this type of matrix or to mandate a laboratory 
to represent you in the exercise.  
Your participation is free of charge. 
In case you plan to pay for the participation of official feed control laboratories belonging 
to your national network, please inform them that their identity will be disclosed to you. 
 
2. The organising team 
The study will be conducted by the European Union Reference Laboratory for Feed 
Additives Control (EURL-FA Control), hosted at the European’s Commission Joint 
Research Centre in Geel, Belgium. 
 
3. Objective 
The major objective of this study is to assess the proficiency of the participating 
laboratories to correctly determine coccidiostats in potentially contaminated feed samples 
and also at authorised level. This aim will be achieved by conducting an inter-comparison 
study in which the laboratories analyse feed samples applying the analytical methods 
referred to in the respective authorisation legislation or their own analytical method and 
reporting the results to the organiser of the study. The evaluation of the results will show 
which laboratories deliver acceptable results. The proficiency test also includes evaluating 
the capability of the laboratories to carry out the requested analysis within a defined time 
frame. 
 
4. Test material 
Samples are prepared containing typical compound feed fortified with selected authorised 
coccidiostats (Regulation (EC) No 1831/2003, Community Register of Feed Additives 
pursuant to Regulation (EC) No 1831/2003) at cross-contamination or authorised 
concentration level. Each laboratory will have to quantitatively analyse 2 samples and to 
submit the results to the coordinator of the study.  
Prior to sending out the samples to the participants the organising team will have 
demonstrated sufficient homogeneity of the test material by analysing randomly taken 
sub-samples.  
 
5. General outline of the exercise  
The participants are requested to report the results of the analyses together with the 
information about the analytical method applied. Each laboratory will be assigned a 
unique code and only the organiser of the study (EURL-FA Control) knows the key to this 
code. The EURL-FA Control will send out a report on the outcome of the study containing 
information about the score of the laboratories; the personal laboratory keys will be 
individually communicated to each participant.  
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Appropriate statistical tool for data evaluation will be used to investigate the proficiency 
of the laboratories. Statistical assessment of the proficiency of laboratories will be 
evaluated by calculating an individual dimensionless z-score calculated according to ISO 
13528. 
 
p
axxz



 
Where  x  = the value reported by the participant 
 xa  = the assigned value 
 σp = the target standard deviation 
 
The proficiency test is scheduled for the period 15 June 2017 – 25 July 2017. 
The exercise will be completed by the organisation of a workshop opened to all 
participants to the study and to all NRLs for Feed additives. The target date for the 
workshop is 22-23 November 2017. The workshop is free of charge. Travel and 
accommodation costs will be reimbursed for one representative of each National 
reference Laboratory for Feed Additives defined according to Regulation (EC) No 
882/2004 or Regulation (EC) No 1831/2003. 
 
6. Expression of interest 
National Reference Laboratories for Feed Additives (Control) defined according to 
Regulation (EC) No 882/2004 shall participate in the proficiency exercise organised by 
the EURL-FA Control or mandate a representative laboratory to participate on their 
behalf, depending on their expertise. Other official control laboratories may also 
participate in the proficiency exercise if places are still available. The total number of 
participating laboratories may not exceed 30. 
All laboratories are kindly asked to register for participation copying the following URL in 
your navigator: 
https://web.jrc.ec.europa.eu/ilcRegistrationWeb/registration/registration.do?selComparis
on=1743   
The deadline for registration is 26 May 2017. Please kindly fill in the form 
comprehensively. These details will be used for the dispatch of the materials and for any 
further correspondence. 
 
Best regards, 
 
Dr Ursula VINCENT 
Study coordinator, EURL-FA Control 
Functional mailbox: JRC-EURL-FEED-ADDITIVES-CONTROL@ec.europa.eu  
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Annex 2. Accompanying letter 
 
 
 
 
 
27 June 2017 
 
 
Proficiency Test exercise 2017 
 
Determination of four coccidiostats in feed  
at authorised and cross-contamination levels 
 
 
INSTRUCTIONS 
 
The materials you received should be analysed in routine conditions, i.e. utilizing your usual method 
for control.  
Please check the content of the package, fill in and send back the 'List of Contents of the Package' 
form as specified below. 
 
The test materials have been grinded and homogenised; no further pre-treatment is necessary before 
the analysis.  
Analyse the test material you received for the presence and the content of authorised coccidiostats. 
The content should be reported as the concentration (mass fraction) of the respective detected 
coccidiostats in mg kg
-1
 of feed given with 3 decimals. When a coccidiostat is present, its mass 
fraction(s) is as defined in the Regulation (EC) No 1831/2003 for authorized feed additive at additive 
level or in Commission Regulation (EU) No 574/2011 for the cross-contamination level. 
 
Results reporting 
The reporting of results will be opened as of 01.07.2017. To report your results, please copy the URL 
below into your Internet navigator: 
https://web.jrc.ec.europa.eu/ilcReportingWeb 
Type in your participant key and login.  
Do not forget to submit your results when your encoding is complete. 
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Method details 
Reporting your results shall be accompanied by filling in the method questionnaire. Please fill in the 
method questionnaire when reporting your results via https://web.jrc.ec.europa.eu/ilcReportingWeb 
Do not forget to submit your questionnaire when your encoding is complete. 
 
Please note that the deadline for reporting the results is 27 July 2017, the on-line system will be 
closed after this date. 
 
Please remember that the major objective of this study is to assess the proficiency of the participating 
laboratories to correctly determine the presence and the mass fraction of four coccidiostats potentially 
present in feed samples at additive and/or cross-contamination levels authorised in the European 
legislation and to report results in the specified units and accompanied with a compliance statement 
on the analysed samples within a defined time frame. 
 
Any deviation as regards the non-respect of the deadline and/or the specified units for reporting will 
lead to the exclusion of your results from the statistical evaluation. 
 
In Autumn 2017, a draft report including the statistical evaluation of all valid participant results will be 
issued and distributed to all reporting participants. The report will be confidential. The list of 
participating laboratories will be included but any result will be strictly linked only to the laboratory 
code. Each participant will be able to retrieve its results and calculated z-score using its individual 
confidential laboratory code communicated on the list of contents of the package form included in this 
letter. 
 
Finally, a concluding workshop opened to all participants to the study will be organised to close the 
exercise in November 2017 (target date: 22-23.11.2017, 1 day). Participation to the PT and to the 
workshop is free of charge. However, travel and accommodation costs will only be reimbursed for one 
representative of each National reference Laboratory for Feed Additives defined according to 
Regulation (EC) No 882/2004 and Regulation (EC) No 1831/2003. 
 
Collusion statement: Keep in mind that collusion is contrary to professional scientific conduct and 
serves only to nullify the benefits of proficiency tests to customers, accreditation bodies and analysts 
alike. 
 
If you have any question, please contact the EURL-FA (Control), JRC-EURL-FEED-ADDITIVES-
CONTROL@ec.europa.eu. 
 
Kind regards,  
 
 
Dr Ursula VINCENT (Proficiency Test Coordinator) 
EURL for Feed Additives Control 
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Annex 3. Acknowledgement of reception 
 
List of Contents of the Package1 
Acknowledgement of Reception 
 
 
Dear «Title» «Name», 
please find below the list of contents for the proficiency test exercise related to the determination of the 
mass fraction of four coccidiostats in feed at authorised and cross-contamination levels, organised by 
the EURL-Feed Additives (Control), on behalf of DG SANTE (European Commission). 
Please check that the sample codes of the samples you received correspond to those declared on this 
list. The samples should be stored at -18°C / -20°C upon reception and until one hour before the 
analysis, when they are left at room temperature until analysis. 
 
Your laboratory code and your participant key are given below. The laboratory code will be applied to 
your laboratory for the whole PT exercise. 
Use the participant key to login to report your results. 
 
 
Your laboratory code is: «Lab_Code» 
Your participant key is: «PartKey» 
 
 
Number of samples in the package: 2 
 
Sample code Present Y/N 
«MAT_1»  
«MAT_2»  
 
 
Samples received on (dd/mm/yyyy) : 
Content checked on (dd/mm/yyyy) : 
Comments (if applicable) : 
 
Date:      Signature:  
 
                                           
1  Form to fill in, sign and send back to the EURL-Feed additives (control) by electronic mail  
(JRC-EURL-FEED-ADDITIVES-CONTROL@ec.europa.eu) or by fax (+32 14  571 787) 
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Annex 4. Homogeneity of the materials 
10 bottles of each test item were randomly selected. Two aliquots from each bottle were 
extracted and further analysed in duplicate by HPLC-MS/MS at the EURL-FA Control. The 
individual results of the sub-sample duplicates were subjected to analysis of variances 
(ANOVA single factor – F-test). If the F-value obtained from the data set was lower than 
the F-critical, the material was considered adequately homogeneous for the related 
analyte. 
MAT 1 was considered suitable to undergo the PT exercise. For MAT 2, although the F-
values obtained were lower than F-critical, seen the scattering of data and the challenge 
posed by the sample preparation and the sample handling, it was decided that the 
material could not be declared as sufficiently homogeneous to allow a classical 
assessment of the laboratories using z and ζ scores. 
Note: a colour code is applied in the tables of this annex; the RSD % given is calculated 
from the standard deviation of the analytical procedure, whereas the RSD% is calculated 
from the between-sample standard deviation. 
 
Note: the data treatment was performed on the results of the measurements carried out 
for the homogeneity, corrected for purity but not for the moisture content. 
 
 
 
 
Diclazuril in MAT 1 - Poultry feed
Homogeneity study
Bottle Subsample 1 Subsample 2
1 0.0103 0.0095
2 0.0102 0.0084
3 0.0097 0.0093
4 0.0108 0.0109
5 0.0087 0.0091
6 0.0093 0.0098
7 0.0080 0.0096
8 0.0090 0.0089
9 0.0092 0.0102
10 0.0097 0.0080
average 0.01
Anova: Single Factor
SUMMARY
Groups Count Sum Average Variance
Row 1 2 0.019842 0.009921 3.444E-07
Row 2 2 0.018596 0.009298 1.459E-06
Row 3 2 0.019081 0.009541 7.644E-08
Row 4 2 0.021662 0.010831 4.418E-09
Row 5 2 0.017856 0.008928 8.904E-08
Row 6 2 0.019182 0.009591 1.191E-07
Row 7 2 0.017594 0.008797 1.286E-06
Row 8 2 0.01799 0.008995 5.618E-09
Row 9 2 0.019401 0.009701 4.278E-07
Row 10 2 0.017697 0.008849 1.291E-06
ANOVA
Source of Variation SS df MS F P-value F crit
Between Groups 7.02081E-06 9 7.8E-07 1.53 0.258575281 3.02
Within Groups 5.10312E-06 10 5.1E-07
Total 1.21239E-05 19
Standard deviation of the analytical procedure (mg/kg): 0.001
RSD (%): 7.56
Between-sample standard deviation (mg/kg): 0.0004
RSD (%): 3.889
uhomogeneity 0.001
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Narasin in MAT 1 - Poultry feed
Homogeneity study
Bottle Subsample 1 Subsample 2
1 0.70 0.70
2 0.71 0.62
3 0.63 0.63
4 0.63 0.60
5 0.61 0.67
6 0.65 0.65
7 0.65 0.67
8 0.65 0.67
9 0.65 0.72
10 0.72 0.70
average 0.66
Anova: Single Factor
SUMMARY
Groups Count Sum Average Variance
Row 1 2 1.400339659 0.70017 2.041E-05
Row 2 2 1.330024138 0.665012 0.0039346
Row 3 2 1.259994377 0.629997 3.922E-05
Row 4 2 1.230656361 0.615328 0.0002504
Row 5 2 1.284969328 0.642485 0.0019408
Row 6 2 1.301440017 0.65072 5.804E-06
Row 7 2 1.314696488 0.657348 0.0002273
Row 8 2 1.319291879 0.659646 6.276E-05
Row 9 2 1.364333912 0.682167 0.0023145
Row 10 2 1.418938446 0.709469 9.021E-05
ANOVA
Source of Variation SS df MS F P-value F crit
Between Groups 0.015715767 9 0.001746 1.97 0.153658167 3.02
Within Groups 0.008885987 10 0.000889
Total 0.024601753 19
Standard deviation of the analytical procedure (mg/kg): 0.03
RSD (%): 4.51
Between-sample standard deviation (mg/kg): 0.02
RSD (%): 3.132
uhomogeneity 0.02
Monensin in MAT 1 - Poultry feed
Homogeneity study
Bottle Subsample 1 Subsample 2
1 1.19 1.18
2 1.21 1.08
3 1.06 1.07
4 1.07 1.05
5 1.04 1.15
6 1.10 1.10
7 1.12 1.17
8 1.14 1.14
9 1.17 1.15
10 1.18 1.20
average 1.13
Anova: Single Factor
SUMMARY
Groups Count Sum Average Variance
Row 1 2 2.37146 1.18573 2.963E-05
Row 2 2 2.29285 1.146425 0.00808356
Row 3 2 2.128607 1.0643035 1.9763E-05
Row 4 2 2.119394 1.059697 0.00026699
Row 5 2 2.1858 1.0929 0.00571124
Row 6 2 2.199257 1.0996285 9.7285E-06
Row 7 2 2.28858 1.14429 0.00097726
Row 8 2 2.278616 1.139308 3.0218E-05
Row 9 2 2.325768 1.162884 0.00026047
Row 10 2 2.377193 1.1885965 0.000134
ANOVA
Source of Variation SS df MS F P-value F crit
Between Groups 0.039424756 9 0.0043805 2.82 0.060836045 3.02
Within Groups 0.015522864 10 0.0015523
Total 0.05494762 19
Standard deviation of the analytical procedure (mg/kg): 0.04
RSD (%): 3.49
Between-sample standard deviation (mg/kg): 0.04
RSD (%): 3.333
uhomogeneity 0.036
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Nicarbazin in MAT 2 - Poultry feed
Homogeneity study
Bottle Subsample 1 Subsample 2
1 44.47 32.54
2 36.43 19.30
3 35.43 42.59
4 51.49 39.00
5 16.29 40.37
6 33.60 26.48
7 59.17 40.36
8 31.31 21.81
9 38.65 52.27
10 27.84 33.94
average 36.17
Anova: Single Factor
SUMMARY
Groups Count Sum Average Variance
Row 1 2 77.00653105 38.50327 71.23871
Row 2 2 55.72943481 27.86472 146.6074
Row 3 2 78.01898559 39.00949 25.664531
Row 4 2 90.48357824 45.24179 78.006305
Row 5 2 56.66463941 28.33232 290.00276
Row 6 2 60.08210052 30.04105 25.322476
Row 7 2 99.53228682 49.76614 176.97297
Row 8 2 53.11778538 26.55889 45.089609
Row 9 2 90.92154759 45.46077 92.858024
Row 10 2 61.78417977 30.89209 18.586386
ANOVA
Source of Variation SS df MS F P-value F crit
Between Groups 1310.356814 9 145.5952 1.50 0.267658084 3.02
Within Groups 970.3491633 10 97.03492
Total 2280.705977 19
Standard deviation of the analytical procedure (mg/kg): 9.85
RSD (%): 27.24
Between-sample standard deviation (mg/kg): 4.93
RSD (%): 13.624
uhomogeneity 4.93
Narasin in MAT 2 - Poultry feed
Homogeneity study
Bottle Subsample 1 Subsample 2
1 21.455 43.693
2 53.472 24.825
3 37.444 21.884
4 39.578 38.204
5 36.353 36.284
6 36.916 31.949
7 61.447 43.266
8 53.625 48.110
9 48.256 26.267
10 33.373 41.887
average 38.914
Anova: Single Factor
SUMMARY
Groups Count Sum Average Variance
Row 1 2 65.14770828 32.573854 247.270854
Row 2 2 78.29712128 39.148561 410.343106
Row 3 2 59.32733224 29.663666 121.054833
Row 4 2 77.7814892 38.890745 0.9439095
Row 5 2 72.63764096 36.31882 0.00237549
Row 6 2 68.86548061 34.43274 12.3381164
Row 7 2 104.7131215 52.356561 165.273217
Row 8 2 101.7357547 50.867877 15.207223
Row 9 2 74.52277867 37.261389 241.754131
Row 10 2 75.26013147 37.630066 36.2427393
ANOVA
Source of Variation SS df MS F P-value F crit
Between Groups 961.2311226 9 106.80346 0.85 0.588758405 3.02
Within Groups 1250.430505 10 125.04305
Total 2211.661628 19
Standard deviation of the analytical procedure (mg/kg): 11.182
RSD (%): 28.736
Between-sample standard deviation (mg/kg): 5.2880
RSD (%): 13.589
uhomogeneity 5.288
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Annex 5. Stability of the materials 
The stability was evaluated on two series of measurements of each analyte. The first 
series was performed when the materials were homogenised (T0) and the second after 
the completion of the proficiency exercise by all participants and reception of the results 
(T16 weeks). 
The remaining bottles of the test items were kept at -20°C during the whole duration of 
the PT exercise. At the end of the exercise, four bottles of MAT 1 and five bottles of 
MAT 2 were analysed in duplicate. Each replicate was injected twice. 
The one-tailed F-test showed that the variances of the two series were equal. The 
following t-test demonstrated that the mean values of the mass fractions obtained after 
16 weeks were not significantly different to the mean values of the mass fractions at T0 
for each of the analytes. The samples can therefore be considered as stable at the 
recommended storage temperature tested during the whole duration of the PT exercise. 
 
Note:  the data treatment was performed on the results of the measurements carried out 
for the homogeneity, corrected for purity but not for the moisture content. 
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Poultry feed; -20 °C T0 T16  T0 T16  T0 T16 (weeks) 
MAT 1 Monensin Narasin Diclazuril 
 
mg kg
-1
 mg kg
-1
 mg kg
-1
 
Bottle 1 - replicate 1 - 2 injections 
1.190 1.109 0.703 0.618 0.010 0.010 
Bottle 1 - replicate 2 - 2 injections 
1.182 1.040 0.697 0.626 0.010 0.010 
Bottle 2 - replicate 1 - 2 injections 
1.039 1.094 0.611 0.669 0.009 0.009 
Bottle 2 - replicate 2 - 2 injections 
1.146 1.060 0.674 0.591 0.009 0.011 
Bottle 3 - replicate 1 - 2 injections  
1.135 1.038 0.654 0.587 0.009 0.009 
Bottle 3 - replicate 2 - 2 injections  
1.143 1.097 0.665 0.593 0.009 0.010 
Bottle 4 - replicate 1 - 2 injections  
1.102 1.070 0.649 0.589 0.009 0.010 
Bottle 4 - replicate 2 - 2 injections  
1.097 1.135 0.652 0.639 0.010 0.011 
F value (one tail) 0.3697 0.9633 0.6070 
t value (one tail) 0.0180 0.0024 0.0429 
degrees of freedom data set 1 = degrees of freedom of data set 2 = 7 
  degrees of freedom total       = 14 
  Fcrit (P=0.05)       = 3.787 
  
t14 at 95% (P=0.05)       = 2.14 
  
 
Poultry feed; -20 °C T0 T16  T0 T16 (weeks) 
MAT 2 Narasin AL Nicarbazin 
 
mg kg
-1
 mg kg
-1
 
Bottle 1 - replicate 1 - 2 injections 
21.455 21.672 44.471 29.794 
Bottle 1 - replicate 2 - 2 injections 
43.693 38.421 32.535 40.654 
Bottle 2 - replicate 1 - 2 injections 
53.472 36.520 36.426 31.739 
Bottle 2 - replicate 2 - 2 injections 
24.825 54.915 19.303 31.928 
Bottle 3 - replicate 1 - 2 injections  
53.625 22.517 31.307 24.575 
Bottle 3 - replicate 2 - 2 injections  
48.110 24.510 21.811 38.901 
Bottle 4 - replicate 1 - 2 injections  
39.578 42.726 51.486 21.284 
Bottle 4 - replicate 2 - 2 injections  
38.204 35.480 38.996 41.132 
Bottle 5 - replicate 1 - 2 injections 
48.256 35.623 38.646 33.284 
Bottle 5 - replicate 2 - 2 injections 
26.267 22.816 52.274 32.200 
F value (one tail) 0.8842 0.3313 
t value (one tail) 0.1713 0.3328 
degrees of freedom data set 1 = degrees of freedom of data set 2 = 9 
degrees of freedom total       = 18 
Fcrit (P=0.05)       = 3.179 
t18 at 95% (P=0.05)       = 2.10 
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Annex 6. Reported mass fraction results, associated uncertainty, in mg kg-1 of feed and 
coverage factor 
  Monensin Narasin 
xpt ; σpt (%) 1.156 ; 15.5 0.670 ; 16.9 
LAB xi u(xi) k xi u(xi) k 
L02 1.070 0.280 2 0.830 0.170 2 
L03 0.974 0.487 2 0.991 0.496 2 
L04 1.376 0.700 1 0.865 0.400 1 
L05 1.551 0.891 2 0.854 0.320 2 
L06 1.284 0.260 2 0.902 0.180 2 
L07 1.470 0.400 2 0.900 0.300 2 
L08 1.010 0.180 2 0.740 0.150 2 
L10 1.260 0.320 2 0.830 0.210 2 
L11 1.283 0.398 2 0.613 0.172 2 
L13 1.220 30.000 1 0.743 35.000 1 
L14 1.110 0.222 2 0.654 0.131 2 
L15 1.378 1.000 2 1.095 0.330 2 
L17 1.090 0.400 2 0.790 0.292 2 
L18 1.091 0.160 2 0.647 0.109 2 
L19 1.561 0.322 2 0.835 0.215 2 
L20 0.998 0.135 2 0.766 0.205 2 
L21 1.050   0.560   
L22 1.039 0.208 2 0.584 0.117 2 
L23 1.522 0.165 2 0.847 0.080 2 
L24 1.084 0.239 2 0.623 0.141 2 
L25 1.410 0.220 2 0.793 0.142 2 
L26 1.401 0.369 2.09 0.695 0.107 2.06 
L27 1.190   0.690   
L28 1.100 11.000 2 0.430 12.000 2 
L29 1.340 11.100 2 0.590 6.500 2 
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  Diclazuril 
xpt / σpt (%) 0.010 / 22.0 
LAB xi u(xi) k 
L02 0.010 0.003 2 
L03 0.003 0.002 2 
L04 <0.01   
L05 0.005 0.004 2 
L06 <0.005   
L07 0.012 0.004 2 
L08 0.009 0.001 2 
L10 0.016 0.005 2 
L11 0.009 0.002 2 
L13 0.010 40.000 1 
L14 0.011 0.002 2 
L15 0.019 0.006 2 
L17 0.010 0.005 2 
L18 0.010 0.002 2 
L19 0.004 0.001 2 
L20 0.009 0.002 2 
L21 0.010   
L22       
L23 <0.25   
L24 0.008 0.002 2 
L25 0.016 0.003 2 
L26 0.005   
L27 0.010   
L28       
L29 0.009 15.200 2 
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Laboratory performance per analyte - z and ζ scores . 
 
(1) NRL 1: NRLs for Control of feed additives, NRL 2: NRLs for Authorisation of feed additives, OCL: OCLs. 
(2) Green: |z| or |ζ|≤ 2, Orange: 2 < |z| or |ζ| < 3, Red: |z| or |ζ| ≥ 3. 
 
Note: on 17 November 2018, L29 informed having wrongly reported the uncertainties associated to their 
measurements as relative uncertainty (in %) and not as absolute ones (in mg/kg) as requested. The 
information having come after the deadline for reporting the results, Table 2 is therefore not modified to 
take it into account. However, u(xi) should have been 0.15 mg kg
-1, 0.038 mg kg-1 and 0.00014 mg kg-1 
for monensin, narasin, and diclazuril thus re-calculating the zeta-scores with the correct uncertainty 
values would lead to zeta-scores of 2.20; -2.80 and -1.46 for monensin, narasin and diclazuril, 
respectively.  
  
LAB Code LAB Type Monensin Narasin Diclazuril Monensin Narasin Diclazuril
L02 NRL 2 -0.48 1.42 0.21 -0.60 1.83 0.28
L03 NRL 1 -1.01 2.84 -3.12 -0.74 1.29 -4.00
L04 NRL 1 1.22 1.73 0.31 0.49
L05 NRL 1 2.20 1.63 -2.21 0.88 1.14 -2.54
L06 NRL 1 0.71 2.06 0.95 2.51
L07 NRL 1 1.74 2.04 1.16 1.54 1.52 1.20
L08 NRL 1 -0.81 0.62 -0.41 -1.51 0.90 -1.15
L10 NRL 2 0.58 1.42 3.06 0.63 1.50 2.55
L11 NRL 1 0.70 -0.50 -0.08 0.63 -0.64 -0.13
L13 NRL 2 0.35 0.65 0.30 0.00 0.00 0.00
L14 NRL 2 -0.26 -0.14 0.78 -0.40 -0.23 1.41
L15 NRL 1 1.23 3.76 4.49 0.44 2.56 3.12
L17 NRL 1 -0.37 1.07 -0.02 -0.33 0.82 -0.02
L18 OCL -0.36 -0.20 0.21 -0.74 -0.39 0.41
L19 NRL 2 2.25 1.46 -2.64 2.45 1.51 -4.00
L20 NRL 1 -0.88 0.85 -0.27 -2.07 0.92 -0.53
L21 NRL 2 -0.59 -0.97 0.21 -2.92 -4.00 1.16
L22 NRL 2 -0.65 -0.76 -1.07 -1.38
L23 NRL 1 2.03 1.57 4.00 3.92
L24 OCL -0.40 -0.41 -0.74 -0.58 -0.63 -1.46
L25 NRL 2 1.41 1.09 3.06 2.19 1.66 3.80
L26 OCL 1.36 0.22 -2.17 1.36 0.45 -4.00
L27 NRL 2 0.19 0.18 0.21 0.92 0.96 1.16
L28 NRL 2 -0.31 -2.12 -0.01 -0.04
L29 OCL 1.02 -0.71 -0.27 0.03 -0.02 0.00
z-scores ζ-scores
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  Nicarbazin Narasin AL 
xpt ; σpt (%) 37.327 ; 9.2 38.763 ; 9.2 
LAB xi u(xi) k xi u(xi) k 
L02 66.800 6.100 2 64.400 8.200 2 
L03 57.570 14.400 2 32.510 4.800 2 
L04 44.700 14.751 1 42.800 5.564 1 
L05 47.700 9.430 2 33.800 13.400 2 
L06 48.477 14.540 2 55.629 13.910 2 
L07 31.000 7.000 2 42.000 6.000 2 
L08 43.810 8.800 2 65.420 13.100 2 
L10 41.100 6.200 2 41.700 6.300 2 
L11       36.800 7.360 2 
L13 22.000 15.000 1 29.600 15.000 1 
L14 49.400 9.880 2 47.200 9.440 2 
L15             
L17 42.300 3.200 2 45.700 8.400 2 
L18 30.320 2.801 2 38.100 3.501 2 
L19 41.800 3.800 2 38.600 6.800 2 
L20 27.368 5.321 2 36.187 6.746 2 
L21 26.500   21.100   
L22       69.433 10.415 2 
L23 25.827 0.312 2       
L24 30.030 6.216 2 36.465 8.241 2 
L25 42.020 2.100 2       
L26 29.246 2.661 2 55.598 8.562 2.06 
L27 84.000   86.300   
L28 46.500 18.000 2 51.800 12.000 2 
L29 35.900 4.000 2 40.100 6.500 2 
 
Note: As an information, for lab 29, u(xi) should have been 2.6 mg kg
-1 and 1.4 mg kg-1 for narasin and 
nicarbazin, respectively.  
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Figures 1 to 5 represent graphically the results as reported by the participants, in 
mg  kg - 1; the error bars represent the reported expanded uncertainties. The assigned 
range is xpt ± 2 u(xpt), except for MAT2. 
 
Figure 1. Reported concentrations for monensin 
 
(1) the error bars are the associated uncertainties as reported by the participants 
 
Figure 2. Reported concentrations for narasin 
 
(1) the error bars are the associated uncertainties as reported by the participants 
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Figure 3. Reported concentrations for diclazuril 
 
(1) the error bars are the associated uncertainties as reported by the participants 
 
Figure 4. Reported concentrations for nicarbazin 
 
(1) the error bars are the associated uncertainties as reported by the participants 
(2) dotted lines: robust standard deviation of measurement results of the participants 
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Figure 5. Reported concentrations for narasin AL 
 
(1) the error bars are the associated uncertainties as reported by the participants 
(2) dotted lines: robust standard deviation of measurement results of the participants; displayed to indicate 
extreme values 
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Annex 7. Reported limits of detection (LOD) and quantification (LOQ) in mg kg-1 for 
each analyte 
 
  Monensin Narasin Diclazuril 
LAB LOD LOQ LOD LOQ LOD LOQ 
L02 - 0.125 - 0.125 - 0.00625 
L03 0.0525 0.125 0.01 0.04 0.007 0.008 
L04 - 0.05 - 0.05 - 0.01 
L05 0.002  0.005 0.002 0.005 0.001 0.002 
L06 0.010 0.025 0.010  0.025 0.005  0.010 
L07 0.3 0.6 0.2  0.4 0.003 0.006 
L08 0.3 0.9 0.1 0.4 0.001 0.003 
L10 0.1 0.5 0.1 0.5 0.001 0.005 
L11 - 0.625 - 0.350 - 0.005 
L13 0.013  0.025 0.013 0.025 0.003 0.005 
L14 - - - - - - 
L15 - - - - - - 
L17 0.07 0.25 0.13  0.14 0.001  0.002 
L18 0.1 0.2 0.1 0.2 0.001 0.002 
L19 0.04  0.125 0.02  0.07 0.002  0.005 
L20 - 0.625 - 0.350 - 0.005 
L21 0.625 0.625 0.35 0.35 0.005 0.005 
L22 - 0.2  - 0.2  - - 
L23 - 0.25 - 0.25 - 0.25 
L24 0.1  0.1 0.1  0.1 0.003  0.003 
L25 - 0.25  - 0.25 - 0.005 
L26 - - - - - - 
L27 0.25 0.5 0.14 0.28 0.002 0.005 
L28 0.3  1.0 0.4  0.7 - - 
L29 0.10 0.30 0.06 0.2 0.001 0.003 
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  Nicarbazin Narasin AL 
LAB LOD LOQ LOD LOQ 
L02 - 2 - 2.5 
L03 - 0.5 - 0.7 
L04 0.5  20 - 2 
L05 0.02  0.06 0.004 0.01 
L06 0.010 0.025 0.010 0.025 
L07 - - - - 
L08 2  6 5  15 
L10 0.1 0.5 0.1 0.5 
L11 - 3 - 1.5 
L13 2  4 2  4 
L14 - - - - 
L15 - - - - 
L17 2  5 2  5 
L18 0.1 0.2 0.1 0.2 
L19 0.02  0.05 0.02  0.07 
L20 - 5.0 - 0.350 
L21 0.63 0.63 0.35 0.35 
L22 - - - 0.2  
L23 - 0.25 - 0.25 
L24 0.1 0.1 0.1  0.1  
L25 - 3 - - 
L26 - - - - 
L27 0.25 0.5 2.0 5.0 
L28 0.2 0.8 0.3  1.0 
L29 0.10 0.30 0.06 0.2 
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Annex 8. Analytical methods used by participants 
2.1 Is the method used accredited? 
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
Yes L02, L03, L04, 
L07, L10, L11, 
L17, L19, L21, 
L24, L25, L26, 
L28, L29 
L02, L03, L04, 
L07, L10, L11, 
L17, L19, L21, 
L22, L24, L28, 
L29 
L02, L03, 
L08, L10, 
L11, L13, 
L14, L15, 
L17, L18, 
L19, L21, 
L24, L25, 
L29 
L02, L03, L08, 
L10, L11, L13, 
L14, L15, L17, 
L18, L19, L21, 
L22, L24, L25, 
L28, L29 
L02, L03, L08, 
L10, L11, L13, 
L14, L15, L17, 
L18, L19, L21, 
L22, L24, L25, 
L28, L29 
No L05, L06, L08, 
L13, L14, L18, 
L20, L22, L23, 
L27 
L05, L06, L08, 
L13, L14, L18, 
L20, L23, L25, 
L26, L27 
L04, L05, 
L06, L07, 
L20, L22, 
L23, L26, 
L27 
L04, L05, L06, 
L07, L20, L23, 
L26, L27 
L04, L05, L06, 
L07, L20, L23, 
L26, L27 
 
2.2 Is it a multi-analyte method or a single analyte one? 
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
Multi-analyte L05, L06, L08, 
L14, L18, L19, 
L21, L23, L24, 
L29 
L02, L05, L06, 
L08, L14, L17, 
L18, L19, L20, 
L21, L22, L23, 
L24, L28, L29 
L02, L03, L04, 
L05, L06, L07, 
L08, L11, L13, 
L14, L15, L17, 
L18, L19, L20, 
L21, L23, L24, 
L25, L27, L29 
L02, L03, L04, 
L05, L06, L07, 
L08, L11, L13, 
L14, L15, L17, 
L18, L19, L20, 
L21, L22, L24, 
L25, L27, L28 
L02, L03, L04, 
L05, L06, L07, 
L08, L11, L13, 
L14, L15, L17, 
L18, L19, L20, 
L21, L22, L24, 
L25, L27, L28 
Single-analyte L02, L03, L04, 
L07, L10, L11, 
L13, L17, L20, 
L25, L26, L27, 
L28 
L03, L04, L07, 
L10, L13, L26, 
L27 
L10, L26 L10, L26 L10, L26 
Other  L11, L25    
 
2.3 Type of method  
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
HPLC L02, L03, L04, 
L06, L07, L08, 
L10, L11, L13, 
L14, L17, L18, 
L20, L21, L23, 
L24, L25, L26, 
L27, L28, L29 
 
L02, L03, L04, 
L06, L07, L08, 
L10, L11, L13, 
L14, L17, L18, 
L21, L22, L23, 
L24, L27, L28, 
L29 
L02, L03, L04, 
L06, L08, L10, 
L11, L13, L14, 
L17, L18, L21, 
L23, L24, L25, 
L27, L29 
L02, L03, L04, 
L06, L08, L10, 
L11, L13, L14, 
L17, L18, L21, 
L22, L23, L24, 
L25, L27, L28, 
L29 
L02, L03, L04, 
L06, L08, L10, 
L11, L13, L14, 
L17, L18, L21, 
L22, L23, L24, 
L25, L27, L28, 
L29 
Other L05, L19 L05, L19, L20, 
L25, L26 
L05, L07, L15, 
L19, L20, L26 
L05, L07, L15, 
L19, L20, L26 
L05, L07, L15, 
L19, L20, L26 
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4.1 Sample amount used for analysis (g)  
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
1. ≥1–<2 L05, L13, L14, 
L27 
L05, L13, L14, 
L20, L25, L27 
L03, L05, L14, 
L27 
L03, L05, L14, 
L27 
L03, L05, L14, 
L27 
2. ≥2–<5 L04, L06, L07, 
L08, L11, L18, 
L20, L29 
L06, L08, L18, 
L29 
L04, L06, L08, 
L11, L13, L15, 
L17, L18, L20, 
L25, L29 
L04, L06, L08, 
L11, L13, L15, 
L17, L18, L20, 
L25, L29 
L04, L06, L08, 
L11, L13, L15, 
L17, L18, L20, 
L25, L29 
3. ≥5–
<10 
L10, L17, L19, 
L21, L23, L24, 
L25, L28 
L02, L10, L17, 
L19, L21, L22, 
L23, L24, L28 
L02, L07, L19, 
L21, L23, L24 
L02, L07, L19, 
L21, L22, L23, 
L24, L28 
L02, L07, L19, 
L21, L22, L23, 
L24, L28 
4. ≥10–
<20 L02, L26 L04, L11       
5. ≥20–
<50 L03 L03, L07, L26 L10, L26 L10, L26 L10, L26 
 
4.2 Type of extraction  
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - 
CL 
Liquid-solid L02, L03, L05, 
L10, L11, L13, 
L17, L20, L23, 
L24L25, L26, 
L28 
L02, L03, 
L05, L10, 
L11, L13, 
L17, L20, 
L23, L24, 
L25, L26, 
L28 
L02, L03, 
L05, L10, 
L11, L13, 
L20, L23, 
L24, L25, 
L26 
L02, L03, 
L05, L10, 
L11, L13, 
L20, L23, 
L24, L25, 
L26, L28 
L02, L03, 
L05, L10, 
L11, L13, 
L20, L23, 
L24, L25, 
L26, L28 
Ultrasonic 
bath 
L04, L06, L08, 
L14, L18, L19, 
L21, L27, L29 
L06, L08, 
L14, L18, 
L19, L21, 
L22, L27, 
L29 
L06, L08, 
L14, L17, 
L18, L19, 
L21, L27, 
L29 
L06, L08, 
L14, L17, 
L18, L19, 
L21, L22, 
L27, L29 
L06, L08, 
L14, L17, 
L18, L19, 
L21, L22, 
L27, L29 
Other L07 L04, L07 L04, L07, 
L15 
L04, L07, 
L15 
L04, L07, 
L15 
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4.3 Is a dilution performed after extraction? 
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
Yes L06, L08, L13, 
L14, L17, L18, 
L19, L21, L23, 
L24, L27, L28, 
L29 
L06, L08, L11, 
L13, L14, L18, 
L19, L20, L21, 
L22, L23, L24, 
L26, L27, L28, 
L29 
L03, L04, L06, 
L14, L15, L23, 
L26, L29 
L02, L03, 
L04, L06, 
L11, L14, 
L15, L22, 
L23, L24, 
L25, L26, 
L29 
L02, L03, L04, 
L06, L11, L14, 
L15, L22, L23, 
L24, L25, L26, 
L29 
No L02, L03, L04, 
L05, L07, L10, 
L11, L20, L25, 
L26 
L02, L03, L04, 
L05, L07, L10, 
L17, L25 
L02, L05, L07, 
L08, L10, L11, 
L13, L17, L18, 
L19, L20, L21, 
L24, L25, L27 
L05, L07, 
L08, L10, 
L13, L17, 
L18, L19, 
L20, L21, 
L27, L28 
L05, L07, L08, 
L10, L13, L17, 
L18, L19, L20, 
L21, L27, L28 
 
4.4 Solvents used for the extraction  
 Nicarbazin - 
AL 
Narasin - AL Diclazuril Narasin - 
CL 
Monensin - 
CL 
Acetonitrile L05, L14, L19, 
L23 
L05, L14, L19, 
L22, L23 
L05, L14, 
L19, L23 
L05, L14, 
L19, L22, 
L23 
L05, L14, 
L19, L22, 
L23 
Acetonitrile/methan
ol 
L04, L07, L10, 
L17, L18, L20, 
L27 
L18 L07, L15, 
L18, L27 
L07, L15, 
L18, L27 
L07, L15, 
L18, L27 
Acetonitrile/water L03 L20       
Acetonitrile/methan
ol/water 
L02, L08 
L21 
  L08, L21 L08, L21 L08, L21 
Acetonitrile/methan
ol/ 
formic acid 
L06 L06 L06 L06 L06 
Methanol L28 L04*, L17, 
L26 
L02, L17, 
L26 
L02, L17, 
L26 
L02, L17, 
L26 
Methanol/water L13, L25, L29 L02, L03, L07, 
L10, L13, L27, 
L28, L29 
 L13, L25, 
L29 
 L10, L13, 
L25, L28, 
L29 
 L10, L13, 
L25, L28, 
L29 
 
Methanol/water/for
mic acid 
    L03 L03 L03 
HCl in methanol     L10     
Ethanol L24 L24 L24 L24 L24 
Dimethylformamide L26         
Hexane saturated 
with acetate 
    L04 L04 L04 
Not reported L22 L25 L22     
 
 48 
4.5 If Clean-up is performed, please specify the type used 
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
C L04, L21, L03, 
L14, L27, L18, 
L17, L24, L29 
L04, L21, L14, 
L27, L18, L02, 
L25, L17, L24 
L21, L03, L14, 
L27, L18, L02, 
L25, L11, L17 
L21, L03, L14, 
L27, L18, L02, 
L25, L11, L17, 
L24 
L21, L03, L14, 
L27, L18, L02, 
L25, L11, L17, 
L24 
FI L07, L06, L20, 
L13, L08, L11, 
L10 
L07, L06, L22, 
L28, L13, L08, 
L11, L10 
L07, L06, L13, 
L08 
L07, L06, L22, 
L28, L13, L08, 
L10 
L07, L06, L22, 
L28, L13, L08, 
L10 
SPE L05, L26, L28, 
L02, L25, L23 
L05, L03, L26, 
L23 
L05, L26, L24, 
L23, L10 
L05, L23, L26 L05, L23, L26 
FR L19 L19, L20 L19, L20 L19, L20 L19, L20 
Q     L04 L04 L04 
C: centrifugation; FI: filtration; SPE: solid phase extraction; FR: freezing; Q: Quenchers 
 
4.6 If a SPE clean-up is performed, please specify the SPE sorbent 
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
Oasis HLB L05 L05 L05 L05 L05 
Aluminium oxide L02         
Alumina neutral L25, L26,  
L28 
        
Silica (Sep-Pak 
plus) 
  L03       
SupelClean ENVI-18 
6 ml 1g  
    L10     
Silica L23 L23, L26 L23, L24, 
L26 
L23, L26 L23, L26 
 
5.1. HPLC Guard column used?  
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
Yes L02, L06, L08, 
L10, L11, L13, 
L14, L17, L18, 
L20, L21, L24, 
L25, L26, L29 
L02, L06, L08, 
L10, L11, L13, 
L14, L17, L18, 
L20, L21, L22, 
L24, L25, L26, 
L27, L28, L29 
L02, L06, L07, 
L08, L10, L11, 
L13, L14, L17, 
L18, L20, L21, 
L24, L25, L26, 
L29 
L02, L06, L07, 
L08, L10, L11, 
L13, L14, L17, 
L18, L20, L21, 
L22, L24, L25, 
L26, L28, L29 
L02, L06, L07, 
L08, L10, L11, 
L13, L14, L17, 
L18, L20, L21, 
L22, L24, L25, 
L26, L28, L29 
No L03, L04, L05, 
L07, L19, L23, 
L27, L28 
L03, L04, L05, 
L07, L19, L23 
L03, L04, L05, 
L15, L19, L23, 
L27 
L03, L04, L05, 
L15, L19, L23, 
L27 
L03, L04, L05, 
L15, L19, L23, 
L27 
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5.2. HPLC stationary phase 
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
C8 L08, L23 L08, L23 L02, L07, L08, 
L11, L23 
L02, L07, L08, 
L11, L23 
L02, L07, L08, 
L11, L23 
C18  L02, L03, L04, 
L06, L07, L10, 
L11, L13, L14, 
L17, L19, L20, 
L25, L26, L29 
L02, L03, L04, 
L06, L07, L10, 
L11, L13, L14, 
L17, L19, L20, 
L26, L29 
L03, L06, L10, 
L13, L14, L15, 
L17, L19, L20, 
L25, L26, L29 
L03, L06, L10, 
L13, L14, L15, 
L17, L19, L20, 
L25, L26, L29 
L03, L06, L10, 
L13, L14, L15, 
L17, L19, L20, 
L25, L26, L29 
C18-HL L21 L21 L21 L21 L21 
Licrospher 
100 RP-18e 
  L27       
Waters 
Acquity 
BEH C18 
L27   L27 L27 L27 
Acquity 
UPLC BEH 
Phenyl 
L05 L05 L05 L05 L05 
Acquity 
UPLC BEH  
  L22   L22 L22 
Phenyl L18 L18 L18 L18 L18 
Waters 
186005614 
    L04 L04 L04 
RP L24 L24 L24 L24 L24 
Silica   L28   L28 L28 
Silica w 
octadecyl 
derivative 
L28         
Not 
reported 
L22 L25 L22     
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5.3. Mobile phase programme  
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
Isocratic L02, L03, L04, 
L07, L10, L11, 
L17, L20, L28 
L07  L28 L28 
Gradient L05, L06, L08, 
L13, L14, L18, 
L19, L21, L23, 
L24, L25, L26, 
L27, L29 
L05, L06, L08, 
L13, L14, L18, 
L19, L20, L21, 
L22, L23, L24, 
L25, L26, L27, 
L29 
L02, L03, L04, 
L05, L06, L07, 
L08, L10, L11, 
L13, L14, L15, 
L17, L18, L19, 
L20, L21, L23, 
L24, L25, L26, 
L27, L29 
L02, L03, L04, 
L05, L06, L07, 
L08, L11, L13, 
L14, L15, L17, 
L18, L19, L20, 
L21, L22, L23, 
L24, L25, L26, 
L27, L29 
L02, L03, L04, 
L05, L06, L07, 
L08, L11, L13, 
L14, L15, L17, 
L18, L19, L20, 
L21, L22, L23, 
L24, L25, L26, 
L27, L29 
 
5.4. Mobile phase components 
 Monensin – CL Narasin – CL Diclazuril – 
CL 
Narasin – AL Nicarbazin 
- AL 
L02 ACN + H2O ACN + H2O ACN + H2O H2O/acetic 
acid/methanol 
methanol/
H2O 
L03 A: 
MetOH:H2O:formic 
acid (25:75:0,01); 
B: MetOH:HCOOH 
(1%) 
A: 
MetOH:H2O:formic 
acid (25:75:0,01); 
B: MetOH:HCOOH 
(1%) 
A: 
MetOH:H2O:
formic acid 
(25:75:0,01)
; B: 
MetOH:HCO
OH (1%) 
MetOH:CH3COOH 
(925:75) 
ACN"H2O 
(57:43) 
L04       ISO 14183 ISO 15782 
L05 0.1% FA, water, 
ACN 
0.1% FA, water, 
ACN 
0.1% FA, 
water, ACN 
0.1% FA, water, 
ACN 
0.1% FA, 
water, ACN 
L06 H20, MeOH, 0.5% 
HCOOH 
H20, MeOH, 0.5% 
HCOOH 
H20, MeOH, 
0.5% 
HCOOH 
H20, MeOH, 0.5% 
HCOOH 
H20, 
MeOH, 
0.5% 
HCOOH 
L07 H2O MeOH ACN + 
AF 
H2O MeOH ACN + 
AF 
H2O MeOH 
ACN + AF 
MeOH H2O Ac.AC ACN H2O 
L08 NH4Ac, HAc, CH3CN NH4Ac, HAc, CH3CN NH4Ac, HAc, 
CH3CN 
NH4Ac, HAc, 
CH3CN 
NH4Ac, 
HAc, 
CH3CN 
L10 acetic acid in 
water/MeOH 
acetic acid in 
water/MeOH 
formic acid 
in water/Acn 
acetic acid in 
water/MeOH 
formic acid 
in 
water/Acn 
L11 0.1% Formic acid 0.1% Formic acid 0.1% Formic 
acid 
MeOH/H20/Acetic 
acid 
65%ACN 
35%H2O 
L13 ACN, Water, 
NH4Acetat 
ACN, Water, 
NH4Acetat 
ACN, Water, 
NH4Acetat 
ACN, Water, 
NH4Acetat 
ACN, 
Water, 
NH4Acetat 
 51 
5.4. Mobile phase components 
 Monensin – CL Narasin – CL Diclazuril – 
CL 
Narasin – AL Nicarbazin 
- AL 
L14 water, MeOH, ACN, 
FA 
water, MeOH, ACN, 
FA 
water, 
MeOH, ACN, 
FA 
water, MeOH, 
ACN, FA 
water, 
MeOH, 
ACN, FA 
L15 Aceticacid/H2O/Me
OH 
Aceticacid/H2O/Me
OH 
Aceticacid/H
2O/MeOH 
- - 
L17 MeCN: 0,01 M 
NH4COOH pH 4 
MeCN: 0,01 M 
NH4COOH pH 4 
MeCN: 0,01 
M NH4COOH 
pH 4 
MeOH MeCN:H20 
L18 FOA 0.1%-MeOH-
ACN 
FOA 0.1%-MeOH-
ACN 
FOA 0.1%-
MeOH-ACN 
FOA 0.1%-MeOH-
ACN 
FOA 0.1%-
MeOH-ACN 
L19 ACN, H2O, formic 
acid 
ACN, H2O, formic 
acid 
ACN, H2O, 
formic acid 
ACN, H2O, formic 
acid 
ACN, H2O, 
formic acid 
L20 H2O/ACN-MeOH 
formic acid 
H2O/ACN-MeOH 
formic acid 
H2O/ACN-
MeOH formic 
acid 
H2O/ACN-MeOH 
formic acid 
water/acet
onitrile 
L21 Formic Acid: H2O: 
MeOH 
Formic Acid: H2O: 
MeOH 
Formic Acid: 
H2O: MeOH 
Formic Acid: H2O: 
MeOH 
Formic 
Acid: H2O: 
MeOH 
L22 Methanol,water,for
micacid 
Methanol,water,for
micacid 
  Methanol,water,for
micacid 
  
L23 A 0.1% formic acid 
in water and B 
0.1% formic acid in 
acetonitrile 
A 0.1% formic acid 
in water and B 
0.1% formic acid in 
acetonitrile 
A 0.1% 
formic acid 
in water and 
B 0.1% 
formic acid 
in 
acetonitrile 
  A 0.1% 
formic acid 
in water 
and B 
0.1% 
formic acid 
in 
acetonitrile 
L24 Formic acid 0.1 % - 
ACN 
Formic acid 0.1 % - 
ACN 
Formic acid 
0.1 % - ACN 
Formic acid 0.1 % 
- ACN 
Formic acid 
0.1 % - 
ACN 
L25 Formic acid sodium 
acetat 
Formic acid sodium 
acetat 
Formic acid 
sodium 
acetat 
  acetic acid 
L26 CH3CN-Formic Acid CH3CN-Formic Acid CH3CN-
Formic Acid 
CH3CN-Formic 
Acid 
CH3CN-
Buffer 
L27 ACN/MeOH 
(1:1)/0.05 PFPA+ 
ACN/MeOH 
(1:1)/0.05 PFPA+ 
ACN/MeOH 
(1:1)/0.05 
PFPA+ 
MEOH/amonium 
acetate 
ACN/MeOH 
(1:1)/0.05 
PFPA+ 
L28 Methanol, water, 
acetic acid, sulfuric 
acid, vanillin 
Methanol, water, 
acetic acid, sulfuric 
acid, vanillin 
  Methanol, water, 
acetic acid, 
sulfuric acid, 
vanillin 
Water, 
Acetonitrile 
L29 A: H2O 0.1%FA // 
B: MeOH 
A: H2O 0.1%FA // 
B: MeOH 
A: H2O 
0.1%FA // 
B: MeOH 
A: H2O 0.1%FA // 
B: MeOH 
A: H2O 
0.1%FA // 
B: MeOH 
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5.5. Mobile phase flow rate  
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
≥0.2 – 
<0.5 
L06, L07, L08, 
L13, L14, L18, 
L21, L24, L27, 
L29 
L06, L08, L13, 
L14, L18, L20, 
L21, L22, L24, 
L26, L27, L29 
L02, L04, L06, 
L07, L08, L13, 
L14, L15, L17, 
L18, L20, L21, 
L24, L25, L26, 
L27, L29 
L02, L04, L06, 
L07, L08, L13, 
L14, L15, L17, 
L18, L20, L21, 
L22, L24, L25, 
L26, L27, L29 
L02, L04, L06, 
L07, L08, L13, 
L14, L15, L17, 
L18, L20, L21, 
L22, L24, L25, 
L26, L27, L29 
≥0.5 – 
<0.7 
L05, L19, L23 L03, L05, L19, 
L23 
L03,L05, L11, 
L19, L23 
L03, L05, L11, 
L19, L23 
L03, L05, L11, 
L19, L23 
≥0.7 – 
<1 
L03, L10, L17 L02, L04, L07, 
L10, L11, L17, 
L28 
L10 L10, L28 L10, L28 
≥1 L02, L04, L11, 
L20, L25, L26, 
L28 
L25       
 
5.6. HPLC injection volume (µl)  
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
≤ 5 L23  L23 L23 L23 
≥5 – 
<10 
L05, L06, L08, 
L13, L14, L18, 
L21, L23, L24, 
L27, L29 
L05, L06, L08, 
L13, L14, L18, 
L21, L22, L23, 
L24, L26, L29 
L04, L05, L06, 
L08, L14, L17, 
L18, L21, L23, 
L24, L25, L26, 
L27, L29 
L04, L05, L06, 
L08, L14, L17, 
L18, L21, L22, 
L23, L24, L25, 
L26, L27, L29 
L04, L05, L06, 
L08, L14, L17, 
L18, L21, L22, 
L23, L24, L25, 
L26, L27, L29 
≥10 – 
<25 
L02, L04, L07, 
L11, L17, L19, 
L25, L26, L28 
L07, L19, L20, 
L25 
L02, L07, L10, 
L11, L13, L15, 
L19, L20 
L02, L07, L11, 
L13, L15, L19, 
L20 
L02, L07, L11, 
L13, L15, L19, 
L20 
≥25 – 
<50 
L10         
≥50 – 
<100 
L03, L20 L L02, L03, 
L17 
L03 L03 L03 
≥100   L04, L10, L11, 
L27, L28 
  L10, L28 L10, L28 
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5.7. Column temperature  
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
ambient L02, L04, L26, 
L27 
L02, L04 L02, L27 L02, L27 L02, L27 
≥ ambient 
– <50 
L03, L06, L07, 
L10, L11, L13, 
L14, L17, L18, 
L19, L20, L21, 
L23, L24, L25, 
L28, L29 
L03, L06, 
L07, L10, 
L11, L13, 
L14, L17, 
L18, L19, 
L20, L21, 
L23, L24, 
L25, L26, 
L27, L28, L29 
L03, L04, 
L06, L07, 
L10, L11, 
L13, L14, 
L15, L18, 
L19, L20, 
L21, L23, 
L24, L25, 
L26, L29 
L03, L04, L06, 
L07, L10, L11, 
L13, L14, L15, 
L18, L19, L20, 
L21, L23, L24, 
L25, L26, L28, 
L29 
L03, L04, L06, 
L07, L10, L11, 
L13, L14, L15, 
L18, L19, L20, 
L21, L23, L24, 
L25, L26, L28, 
L29 
≥50 L05, L08 L05, L08, L22 L05, L08, L17 L05, L08, L17, 
L22 
L05, L08, L17, 
L22 
 
5.8. Autosampler temperature  
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
<10 L04, L21 L04, L21 L04, L21 L04, L21 L04, L21 
≥10 – 
<15 
L06, L07, L14, 
L23, L25 
L06, L07, 
L11, L14, 
L20, L23, L25 
L06, L07, 
L11, L14, 
L15, L20, 
L23, L25 
L06, L07, L11, 
L14, L15, L20, 
L23, L25 
L06, L07, L11, 
L14, L15, L20, 
L23, L25 
≥15 – < 
ambient 
L05, L11, L17, 
L19, L24, L29 
L05, L17, 
L19, L22, 
L24, L29 
L05, L17, 
L19, L24, L29 
L05, L17, L19, 
L22, L24, L29 
L05, L17, L19, 
L22, L24, L29 
≥ 
ambient 
– <20 
L03, L13, L18, 
L26, L27 
L03, L13, 
L18, L26, L27 
L03, L13, 
L18, L26, L27 
L03, L13, L18, 
L26, L27 
L03, L13, L18, 
L26, L27 
≥20 L08, L10 L08, L10 L08, L10 L08, L10 L08, L10 
Off L02, L20, L28 L02, L28 L02  L02, L28 L02, L28 
 
  
 54 
 
6. Specrophotometric detection (nm) 
 Nicarbazin - AL Narasin - AL Diclazuri
l 
Narasin - CL Monensin - CL 
265-345 L26     
344 L02     
350-351 L03, L04, L07, 
L10, L11, L17, 
L20, L25, L28 
        
520   L07, L10   L10, L28 L10, L28 
592   L02, L04, L07, 
L10, L11, L17, 
L27, L28 
      
600   L03       
 
8.1. Mass spectrometry detector type 
 Nicarbazin - 
AL 
Narasin - AL Diclazuril Narasin - CL Monensin - CL 
Single 
quadrupole 
     
Triple 
quadrupole 
L05, L06, L08, 
L13, L18, L19, 
L21, L23, L24, 
L27, L29 
L05, L06, 
L08, L13, 
L18, L19, 
L20, L21, 
L22, L23, 
L24, L26, L29 
L02, L03, 
L04, L05, 
L06, L07, 
L08, L10, 
L11, L13, 
L15, L17, 
L18, L19, 
L20, L21, 
L23, L24, 
L25, L26, 
L27, L29 
L02, L03, L04, 
L05, L06, L07, 
L08, L11, L13, 
L15, L17, L18, 
L19, L20, L21, 
L22, L23, L24, 
L25, L26, L27, 
L29 
L02, L03, L04, 
L05, L06, L07, 
L08, L11, L13, 
L15, L17, L18, 
L19, L20, L21, 
L22, L23, L24, 
L25, L26, L27, 
L29 
H-RMS L14 L14 L14 L14 L14 
Other L02, L03, L04, 
L07, L10, L11, 
L17, L20, L25, 
L26 
L02, L03,  
L04, L07, 
L10, L11, 
L17, L25, L27 
  L10 L10 
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 9.1. Calibration type       
 Nicarbazin - 
AL 
Narasin - AL Diclazuril Narasin - CL Monensin - CL 
External 
calibration 
L02, L03, L04, 
L07, L10, L11, 
L13, L17, L20, 
L24, L25, L26, 
L28 
L02, L03, 
L04, L07, 
L10, L11, 
L13, L17, 
L24, L25, 
L26, L28 
L03, L24, 
L26 
L03, L10, L24, 
L26, L28 
L03, L10, L24, 
L26, L28 
Marix-
match 
calibration 
L05, L14, L18, 
L23 
L05, L14, 
L18, L20, 
L23, L27 
L02, L04, 
L05, L07, 
L11, L14, 
L18, L20, 
L23, L25, 
L27 
L02, L04, L05, 
L07, L11, L14, 
L18, L20, L23, 
L25 L27 
L02, L04, L05, 
L07, L11, L14, 
L15, L18, L20, 
L23, L25, L27 
Standard 
addition 
L06, L08, L19, 
L21, L27, L29 
L06, L08, 
L19, L21, 
L22, L29 
L06, L08, 
L10, L13, 
L15, L17, 
L19, L21, 
L29 
L06, L08, L13, 
L15, L17, L19, 
L21, L22, L29 
L06, L08, L13, 
L17, L19, L21, 
L22, L29 
 
9.2. Use of an internal standard  
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
Yes L05, L06, L08, 
L19, L21, L23, 
L24, L27, L29 
L05, L06, L08, 
L19, L20, L21, 
L23, L24, L29 
L02, L05, L06, 
L07, L08, L10, 
L11, L15, L17, 
L18, L19, L20, 
L21, L23, L24, 
L25, L27, L29 
L02, L05, L06, 
L07, L08, L17, 
L19, L20, L21, 
L23, L24, L25, 
L27, L29 
L02, L05, L06, 
L07, L08, L17, 
L19, L20, L21, 
L23, L24, L25, 
L27, L29 
 
No L02, L03, L04, 
L07, L10, L11, 
L13, L14, L17, 
L18, L20, L25, 
L26, L28 
L02, L03, L04, 
L07, L10, L11, 
L13, L14, L17, 
L18, L22, L25, 
L26, L27, L28 
L03, L04, L13, 
L14, L26 
L03, L04, L10, 
L11, L13, L14, 
L15, L18, L22, 
L26, L28 
L03, L04, L10, 
L11, L13, L14, 
L15, L18, L22, 
L26, L28 
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9.3. Internal standard used  
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
Nigericin  L05, L06, L08, 
L19, L20, L21, 
L23, L24, L29 
L19 L02, L05, L06, 
L07, L08, L17, 
L19, L20, L21, 
L23, L24, L25, 
L27, L29 
L02, L05, L06, 
L07, L08, L17, 
L19, L20, L21, 
L23, L24, L25, 
L27, L29 
diclazuril-
IS 
    L02     
bis-
diclazuril 
    L06, L07, L08, 
L10, L11, L20, 
L21, L24, L29 
    
Methyl 
diclazuril 
    L05, L15, L17, 
L27 
    
Toltrazuril
-d3 
    L18     
DNC-d8 L05, L06, L08, 
L19, L21, L23, 
L24, L27, L29 
  L23, L25     
 
9.4. Was the same method used for the remaining sample? 
 Nicarbazin - AL Narasin - AL Diclazuril Narasin - CL Monensin - CL 
Yes L02, L05, L06, 
L08, L11, L13, 
L14, L18, L19, 
L21, L23, L24, 
L25, L26, L27, 
L28, L29 
L02, L05, L06, 
L08, L10, L11, 
L13, L14, L18, 
L19, L20, L21, 
L22, L23, L24, 
L25, L26, L27, 
L28, L29 
L02, L05, L06, 
L07, L08, L11, 
L13, L14, L15, 
L18, L19, L20, 
L21, L23, L24, 
L25, L26, L27, 
L29 
L02, L05, L06, 
L07, L08, L10, 
L11, L13, L14, 
L15, L18, L19, 
L20, L21, L22, 
L23, L24, L25, 
L26, L27, L28, 
L29 
L02, L05, L06, 
L07, L08, L10, 
L11, L13, L14, 
L15, L18, L19, 
L20, L21, L22, 
L23, L24, L25, 
L26, L27, L28, 
L29 
No L03, L04, L07, 
L10, L17, L20 
L03, L04, L07, 
L17 
L03, L04, L10, 
L17 
L03, L04, L17 L03, L04, L17 
 
  
 57 
9.5. Method used then (answer to 9.4 is no)? 
 Monensin - CL Narasin - CL Diclazuril Narasin - AL Nicarbazin - AL 
L03 LC-MS/MS LC-MS/MS LC-MS/MS HPLC-UV - EN 
ISO 14183 
HPLC-UV - EN 
ISO 15782 
L04 Own method Own method Own method ISO 14183 ISO 15782 
L07 internal method internal method internal 
method 
ISO 14183 NF EN 15782 
L10 HPLC-
postcolumnUV 
HPLC-
postcolumnUV 
HPLC-MS/MS HPLC-
postcolumnUV 
HPLC-PDA 
L13       use of a 
dilutions step 
use of a 
dilutions step 
L20 LC-MS/MS LC-MS/MS LC-MS/MS LC-MS/MS HPLC-UV/DAD 
 
9.6. How did you estimate your measurement uncertainties? (multiple choice) 
Uncertainty budget (ISO GUM) L04 
From in-house method validation L03, L06, L10, L13, L14, L15, L17, L18, 
L19, L22, L24, L25, L27, L28, L29 
From in-house method validation & 
Measurement of replicates (precision) 
L11 
From in-house method validation, 
Measurement of replicates (precision) & 
From interlaboratory comparison 
L02, L08 
From in-house method validation, 
Measurement of replicates (precision) & 
Other 
L26 
From in-house method validation & Other L07, L20 
Measurement of replicates (precision) L05, L23 
Other L21 
 
9.7. Do you usually provide an uncertainty statement to your customers? 
Yes L02, L03, L04, L06, L07, L10, L11, L13, L14, L15, L17, L18, L19, L20, L22, 
L24, L25, L26, L27, L29 
No L05, L08, L21, L23, L28 
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10. Did you correct your result for moisture content? 
Yes L04, L18, L19, L20, L24, L25, L26 
No L02, L03, L05, L06, L07, L08, L10, L11, L13, L14, L15, L17, L21, L22, L23, 
L27, L28, L29 
 
11. Did you correct your result for recovery? 
Yes L04, L07, L10, L14, L15, L19, L22, L25, L26, L27 
No L02, L03L05, L06, L08, L11, L13, L17, L18, L20, L21, L23, L24, L28, L29 
 
12. How did you estimate the recovery? 
Using a spike L02, L03, L04, L05, L06, L07, L08, L10, L13, 
L14, L17, L18, L19, L20, L21, L23, L24, L25, 
L26, L27, L28 
Other L11 
matrix matched standard callibration L15, L29 
From validation study, spiking 
experiments and reference material 
L22 
 
13. How many analyses of this type does your laboratory perform on a yearly 
basis? 
 Nicarbazin - 
AL 
Narasin - AL Diclazuril Narasin - CL Monensin - CL 
Never L14, L18, L22, 
L23, L27 
L14, L18, L20, 
L23 
L22, L23 L23 L23 
0-49 L02, L04, L05, 
L07, L08, L11, 
L13, L17, L19, 
L20, L25, L28 
L04, L05, L07, 
L08, L11, L13, 
L19, L22, L25, 
L27 
L05, L08, L11, 
L13, L14, L19, 
L20, L27,  
L05, L08, L11, 
L13, L14, L19, 
L20, L22, L27 
L05, L08, L11, 
L13, L14, L19, 
L20, L22, L27,  
 
50-249 L03, L06, L10, 
L21, L24, L29 
L02, L03, L06, 
L10, L17, L21, 
L24, L29 
L03, L04, L06, 
L07, L10, L15, 
L17, L18, L21, 
L24, L25, L26, 
L29 
L03, L04, L06, 
L07, L10, L15, 
L17, L18, L21, 
L24, L25, L29 
L03, L04, L06, 
L07, L10, L15, 
L17, L18, L21, 
L24, L25, L29 
250-999 L26 L26, L28 L02 L02, L26, L28 L02, L26, L28 
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14. Did your laboratory participate in other PTs for this type of 
analysis? 
Yes L02, L03, L04, L06, L07, L08, L10, L11, L13, L15, L17, L19, L20, 
L21, L22, L24, L25, L26, L28, L29 
No L05, L14, L18, L23, L27 
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Mass spectrometry detection – Parent & daughter ions 
 Narasin – AL Nicarbazin – AL 
 
1. parent 
ion m/z 
2. 
daughter 
ion 1 m/z 
3. 
daughter 
ion 2 m/z 
1. parent 
ion m/z 
2. 
daughter 
ion 1 m/z 
3. 
daughter 
ion 2 m/z 
L04 787.4 431.1 531.2 300.9 136.8 106.8 
L05 787.5 431.2 431.2 300.9 136.9 106.9 
L06             
L07 782.56 747.4 729.5 301.06 136.8 106.9 
L11 782,4 747,5 729,6 301,0 106,9 136,9 
L13 787.4967 431.2393   301.0578 137.0344   
L17 787 431 531 301 137 107 
L18 787,696 431,264 531,374 301,032 136,954 106,92 
L19 787.7 431.4 279.3 n/a n/a n/a 
L20 788 431 531 301 107 137 
L21 787.3 431.1 531.1       
L22 787 431 531 301 137 107 
L23 787 431 531 301 137 107 
L24             
L25 787.5 431.2 531.3       
L26       301.2 137.0 107.0 
L27 787.5 531.2 431.2 301.1 107.0 137.0 
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Monensin – CL Narasin – CL Diclazuril – CL 
 
1. parent 
ion m/z 
2. 
daughter 
ion 1 m/z 
3. 
daughter 
ion 2 m/z 
1. parent 
ion m/z 
2. 
daughter 
ion 1 m/z 
3. 
daughter 
ion 2 m/z 
1. parent 
ion m/z 
2. 
daughter 
ion 1 m/z 
3. daughter 
ion 2 m/z 
L02 693.4 461.1 479.2 787.5 431.0 530.8 406.9 336.0 337.1 
L03 693,4 461,2 479,2 787,6 431,2 279,1 404,9 
(406,9) 
334,0 336,0 
L04 693.5 461.4 501.4 787.6 431.3 531.3 405.1 
(407.1) 
334.1 
(336.1) 
  
L05 693.3 675.3 461.1 787.4 431.1 531.2 404.9/406.9 333.85 335.85 
L06 693.5 461.2 479.2 787.5 431.2 431.2 404.9 333.9 298.9 
L07 693.3 461.2 479.2 787.4 431.2 531.4 406.8/404.8 335.9 333.9 
L08 688.43 635.4 461.3 782.56 747.4 729.5 406.99 335.6 404.99 to 
333.7 L11 693.4 675.3 461.5 787.4 531.5 431.4 405.0 333.9 335.9 
L13 688,4 635,5 461,3 782,4 747,5 729,6 405,0/407,0 333,7 335,8 
L14 693.4184 461.2862   787.4967 431.2393   404.9718 333.9717   
L15 693.3 501.3 581.2 787.4 431.2 279.1 405.0 334.0 299.0 
L17 693 675 461 787 431 531 405 334 407/336 
L18 693 461 675 787 431 531 405 334 336 
L19 693,532 479,29 461,334 787,696 431,264 531,374 404,9 334   
L20 693.7 675.7 461.5 787.7 431.4 279.3 407.2/405.2 336.1 334.1 
L21 693 461 479 788 431 531 405/407 334 336 
L22 693.2 461.1 479.2 787.3 431.1 531.1       
L23 693 461 479 787 431 531 405 334 336 
L24 693 461 479 787 431 531 405 334 299 
L25 693.3 675.6 461.5 787.5 431.3 279.2 406.0 334.2 336.2 
L26 693.42 675.4 461.2 787.5 431.2 531.3 409.97 335 299 
L27 693.5 675.6 461.3 787.6 431.1 531.4 407.5 
/405.0 
336.0 334.1 
L29 693.4 479.2 461.2 787.5 531.2 431.2 404.9/406.9 335.9 333.9 
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